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ABSTRACT 
Few studies have assessed the optimum second line highly active anti-retroviral therapy 
(HAART) regimen in patients who had failed on the first-line HAART in resource-limited 
settings. This study aimed to compare the Protease inhibitor (PI)-based second line 
HAART regimens used in one clinic in Trinidad by comparing immunological, virological 
and clinical outcomes of patients on the different second line HAART regimens.  
The records of 35 treatment-experienced patients, over 21years of age and on PI-based 
regimens for at least six months, were analysed using SPSS version 20.  
The regimen containing TDF/FTC/AZT/LPV/r proved to produce superior outcomes 
compared to the other second line regimens.  
Due the small number of usable patients’ records, the findings cannot be generalised 
but indicate directions for future studies attempting to compare the treatment outcomes 
of different second line HAART regimens. 
 
Keywords: Highly active anti-retroviral treatment (HAART), 1st HAART regimens, 2nd 
line HAART regimens, resistance to anti-retroviral drugs, treatment adherence 
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CHAPTER 1 
 
ORIENTATION TO THE STUDY 
 
1.1   INTRODUCTION 
 
Human immunodeficiency virus (HIV) infections and acquired immunodeficiency 
syndrome (AIDS) are prevalent throughout the Republic of Trinidad and Tobago, 
which is an archipelagic state in the southern Caribbean, lying just off the coast of 
northeastern Venezuela and south of Grenada in the Lesser Antilles. It shares 
maritime boundaries with Barbados to the northeast, Grenada to the northwest, 
Guyana to the southeast, and Venezuela to the south and west. According to the 
Global Aids Response Trinidad and Tobago Country Progress Report (UNAIDS 
2012:3), an estimated 22 787 people were living with HIV, with an estimated 
prevalence rate of 1.5% at the end of 2010, in Trinidad (Trinidad &Tobago 2013).  
 
Symptoms of HIV/AIDS include diarrhoea, weight loss, oral thrush, skin rashes, 
tuberculosis and malignancies.  Patients are grouped based on clinical presentation 
into World Health Organization (WHO 2010:27-28) stages 1, 2, 3 and 4, in increasing 
order of progression of the disease, as summarised in table 1.1. 
 
TABLE 1.1: WHO CLINICAL STAGING OF HIV DISEASE IN ADULTS AND ADOLESCENTS. 
CLINICAL STAGE 1 
Asymptomatic 
Persistent generalised lymphadenopathy 
CLINICAL STAGE 2 
Moderate unexplained weight loss (under 10% of presumed or measured body weight) 
Recurrent respiratory tract infections (sinusitis, tonsillitis, otitis media, pharyngitis 
Herpes zoster 
Angular cheilitis (inflammation of the corners of the lip) 
Recurrent oral ulcerations 
Papular pruritic eruptions 
Seborrhoeic dermatitis 
Fungal nail infections 
2 
 
CLINICAL STAGE 3 
Unexplained severe weight loss (over 10% of presumed or measured body weight ) 
Unexplained chronic diarrheoa for longer than one month 
Unexplained persistent fever (intermittent or constant for longer than one month ) 
Persistent oral candidiasis 
Oral hairy leukoplakia 
Pulmonary tuberculosis 
Severe bacterial infections (such as pneumonia, empyaema, meningitis, pyomyositis, bone and/or 
joint infection, bacteraemia, severe pelvic inflammatory disease) 
Acute necrotising ulcerative stomatitis, gingivitis or periodontitis 
Unexplained anaemia (below 8mg/dl), neutropenia (below 0.5 x 109/l) and/or chronic 
thrombocytopaenia (below  50 X 109/l)  
CLINICAL STAGE 4  
HIV wasting syndrome 
Pneumocystic jiroveci pneumonia 
Recurrent severe bacterial pneumonia 
Chronic herpes simplex infection (orolabial, genital, oro-ano-rectal of more than one month’s duration 
or visceral at any time) 
Oesophageal candidiasis (or candidiasis of trachea, bronchi or lungs ) 
Extrapulmonary tuberculosis 
Kaposi sarcoma 
Cytomegalovirus disease (retinitis, or infection of other organs, excluding the liver, spleen and lymph 
nodes) 
Central nervous system toxoplasmosis 
HIV encephalopathy 
Extra-pulmonarycryptococcosis, including meningitis 
Disseminated non-tuberculous mycobacteria infection 
Progressive multifocal leuco-encephalopathy 
Chronic cryptosporidiosis 
Chronic isosporiasis 
Disseminated mycosis (histoplasmosis, coccidiomycosis) 
Recurrent septicaemia (including non-typhoid salmonella) 
Lymphoma (cerebral or B cell non-Hodgkin) 
Invasive cervical carcinoma 
Atypical disseminated leishmaniasis 
Symptomatic HIV-associated nephropathy or HIV-associated cardiomyopathy- 
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Highly active antiretroviral therapy (HAART), a treatment paradigm using three or 
more antiretroviral (ARV) drugs in combination, has reduced the morbidity and 
mortality of patients with HIV/AIDS (WHO 2007), with immunological (increased CD4 
counts), virological (decreased viral load counts), and clinical (improved clinical 
state) responses in developing countries such as Trinidad (Wools-Kaloustian, 
Kimaiyo, Diero, Siika, Sidle, Yiannoutsos, Musick, Einterz, Fife & Tierney 2006:41-8), 
similar to that in developed countries. Mc Mahon, Elliot, Bertagnolio, Kubiak  & 
Jordan ( 2013) in a systematic review of studies from low and middle income 
countries revealed 71% of patients on the intention-to-treat analysis and 84% in the 
on-treatment analysis had attained viral suppression 12 months after ARV initiation 
and this compared favourably with outcomes in high-income countries 
 
When first line ARVs fail, provided the patient has adhered to his/her antiretroviral 
therapy (ART) regimens, second line ARV combinations need to be used. The WHO 
(2010:53-57) states that a new second line regimen has to involve drugs that retain 
activity against the patient’s virus strain and should ideally include a minimum of 
three active drugs, with at least one from a new class of ARVs, in order to increase 
the likelihood of treatment success and minimise the risk of cross resistance 
(Ministry of Health of Trinidad and Tobago [MOHTT] 2009:9). 
 
1.2   BACKGROUND INFORMATION ABOUT THE RESEARCH PROBLEM 
 
1.2.1   The source of the research problem 
 
Interest in the research topic arose because of the documented need for research 
comparing the treatment outcomes of second line ARVs. The WHO (2010:56) 
guideline recommends using second line drugs depending on what was used in the 
first line. The MOHTT (2009:9) guidelines also state that it should be assumed that 
drug resistance has occurred to the components of the regimen that the patient was 
taking when failure was diagnosed. Good early outcomes have been observed in 
protease inhibitor-based second line regimens with at least one neucleoside or 
neucleotide reverse transcriptase inhibitor NRTI change.  There is cross resistance 
between Lamivudine (3TC) and Emitricitabine (FTC) and the two drugs are similar in 
activity. Studies proving the efficacy of using either drug, after the other fails in a 
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previous regimen, need to be conducted to provide scientific evidence of the efficacy 
of specific second line ART regimens (MOHTT 2009:9; Pujades-Rodríguez, O’Brien, 
Humblet & Calmy 2008:1305-1312; WHO 2012:11). 
 
The WHO (2010:53) states that few studies were identified in a systematic review, 
conducted with the objective of assessing the optimum second line ART regimen in 
patients failing first line therapy in resource limited settings. There was a need for 
this study to compare the second line regimens used in Trinidad (Humphreys, 
Hernandez & Rutherford 2010). 
 
1.2.2   Background to the research problem 
 
HAART medications have reduced AIDS morbidity and mortality rates (WHO 2007). 
HAART regimens are mostly modified in response to toxicity, intolerance, treatment 
failure or evidence of superiority of another regimen. Non-adherence to ARVs is a 
major cause of failure of any HAART regimen. Patients, proven to be adherent to 
first line ARVs, who show evidence of treatment failure, need to change from the first 
line HAART regimen to the second line regimen containing preferably three new 
drugs, with at least one from a new class. The Trinidad HIV/AIDS treatment and care 
guidelines recommend the use of the preferred first line combination in Trinidad as 
Tenofovir (TDF) and Emitricitabine (FTC), nucleotide and nucleoside reverse 
transcriptase inhibitors (NRTIs) respectively, in a once daily combination pill, 
Truvada, in combination with Efavirenz (EFV), a non-nucleoside reverse 
transcriptase inhibitor (NNRTI), also given once daily. Lamivudine is also sometimes 
used in place of FTC. Some patients who are intolerant of TDF due to renal toxicity 
are given Zidovudine (AZT) and 3TC as NRTI backbone in a combination pill, 
Combivir. Those unable to use AZT because of anaemia use Truvada. Patients 
intolerant of EFV use Nevipapine (NVP) if the CD4 count is less than 250, and a 
protease inhibitor (PI), either Ritonavir (r) boosted Lopinavir (LPV/r) or Atazanavir 
(ATV/r) when the CD4 count exceeds 250 (FDA 2014; MOHTT 2009:8).  
 
When the first line drugs start to fail, after it has been determined that the patient is 
adherent to the medication, they are switched to second line combinations. In 
choosing first line NRTI backbones, it should be considered what should be reserved 
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for the second line NRTI backbone. In supporting this statement, the WHO (2010:53-
57) also states that a new second line regimen has to involve drugs that retain 
activity against the patients’ virus strain and should ideally include a minimum of 
three active drugs, one of them drawn from at least one new class, in order to 
increase the likelihood of treatment success and minimise the risk of cross 
resistance. The WHO (2010:53-57) recommends that the PI class is reserved for use 
in second line regimens in combination with two unused NRTIs. The continued use 
of 3TC or FTC in second line is recommended by some experts because it maintains 
the M184V mutation which confers a viral replication defect or may possess residual 
antiviral activity. Maintaining the M184V mutation is also thought to improve 
sensitisation of the virus to Zidovudine (AZT/ZDV), Stavidine (d4T) and TDF. AZT is 
thought to delay the emergence of K65R mutation which usually confers resistance 
to TDF. Thus, after failure of first line, combination of 3TC or FTC and AZT or TDF is 
thought to provide retained activity of AZT and TDF, while reducing viral fitness and 
replication. The clinical efficacy of this strategy has not been proven. Medecins Sans 
Frontieres (MSF) documented favourable outcomes observed in protease inhibitor-
based second line regimens with at least one NRTI change (Pujades-Rodríguez et al 
2008:1305-1312).  
 
The second line drugs used in Trinidad are completely unused NRTIs and PIs. 
Patients who have previously used TDF and FTC with EFV or NVP are switched to 
AZT, 3TC and LPV/r. Those who used AZT and 3TC with EFV or NVP are switched 
to TDF, FTC and LPV/r. The majority of patients on second line HAART in Trinidad 
are on Truvada and LPV/r or Combivir and LPV/r. However there are several other 
PI-based regimens in use which are more appropriate in certain instances like the 
need to reduce pill burden, a regimen suitable for renal failure or liver toxicity. Some 
patients were also placed on PI-based regimens as first line drugs for certain 
situations such as during pregnancy, intolerance of  NNRTIs, and continuation of PI 
as first line in patients already on PI as first line HAART, who have been transferred 
in from other health care facilities. 
 
This research was a comparison of the PI-based regimens being used in Trinidad in 
order to determine and compare their efficacy. For the purpose of this research, the 
PI-based regimens in use in the San Fernando General Hospital (SFGH) HIV unit 
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were grouped in numbers as shown in table 1.2  (FDA 2014; Humphreys et al 2007; 
MOHTT 2009:9; Warnke, Barreto & Temesgen 2007:1570;  Wools-Kaloustian et al 
2006: 41-8). 
 
Table 1.2:  PI-based regimens in SFGH HIV clinic 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This study provides an opportunity to determine whether the PI-based regimens in 
use in Trinidad are of comparable efficacy. Determining the better combination will 
benefit patients and improve HIV care in Trinidad. The researcher recognised that 
new recommendations for the most ideal regimen to use for first or second line may 
each have their inherent disadvantages such as higher number of doses, intolerable 
side effects and unfavourable drug interactions. It thus leaves room for individualised 
patient care in which regimens are created based on patient presentation, history of 
ARV usage, previous side effects to ARVs as well as resistance test results, if 
available. The results of this research could contribute to the field of HIV/AIDS 
management in Trinidad, and possibly elsewhere in the world, provided that similar 
NUMBER                         REGIMEN 
1 AZT +3TC+ LPV/r 
2 TDF+FTC+LPV/r 
3 TDF+FTC+ATZ/r 
4 TDF+FTC+DRV/r 
5 ddI + 3TC + LPV/r 
6 AZT+3TC+SQV/r 
7 ABC+3TC+LPV/r 
8 TDF+3TC+IDV/r 
9 AZT+3TC+IDV/r 
10 TDF+FTC+AZT+LPV/r 
11 TDF+FTC+SQV/r 
12 ABC+3TC+ATZ/r 
13 TDF+AZT+3TC+LPV/r 
14 TDF+FTC+ABC+LPV/r 
15 TDF+AZT+LPV/r 
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studies have been conducted in other geographic locations. If it is found that all the 
regimens have the same efficacy, it may be advantageous for some patients who 
cannot use some ARVs due to side effects. Thus patients who develop M184V 
mutations could be placed on either regimen with confidence that they would do well.  
 
1.3     RESEARCH PROBLEM 
 
When first line ARVs fail in patients who adhere to the ART regimens, second line 
ARVs are used. The drugs recommended for use for second line in Trinidad are 
completely unused NRTIs and PIs. Patients who have previously used TDF and FTC 
with EFV or NVP are switched to AZT, 3TC and LPV/r. Those who used AZT and 
3TC with EFV or NVP are switched to Truvada and LPV/r. Other second line 
combinations using other PIs are also in use. PI-based regimens are also being used 
for some patients as first line drugs because they could not tolerate NNRTIs, and 
also for pregnant women for the prevention of mother to child transmission of HIV 
(PMTCT). Studies comparing the efficacy of the PI-based HAART regimens in 
Trinidad could not be traced after an extensive search for published literature on the 
topic had been attempted. 
 
Fifteen PI-based HAART regimens are being used in Trinidad but the treatment 
outcomes of these regimens have not been documented.  Consequently it remains 
unknown whether there are differences between the effectiveness of the different PI-
based HAART treatment regimens. This study attempted to provide information 
about these treatment outcomes.  This information could be used when prescribing 
second line ARVs in Trinidad, to ensure that the best possible combinations of ARVs 
with the fewest side-effects are prescribed for specific patients. 
 
1.4    AIM OF THE STUDY 
 
This study attempted to compare the efficacy of different PI-based HAART regimens 
in Trinidad. (Although the title of the dissertation includes Tobago, permission could 
not be obtained to replicate the study in Tobago.  Finances were also too limited to 
repeat the study in Tobago). 
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1.4.1   Research purpose 
 
The purpose of the study was to compare the patients’ treatment outcomes of the PI-
based HAART regimens in Trinidad. Variables, impacting on ARV treatment 
outcomes, such as patients’ treatment adherence levels, baseline as well as 
subsequent CD4 counts and VL levels, and other diseases (opportunistic infections 
and tuberculosis) were considered. 
 
1.4.2   Research Objectives 
 
The study attempted to determine whether the treatment outcomes of the PI-based 
HAART regimens in Trinidad were significantly different from each other. 
 
The study aimed to compare the treatment outcomes of the PI-based HAART 
regimens in Trinidad by comparing the following aspects for patients on the 
regimens: 
• baseline (when started on PI-based HAART regimens) CD4 and VL counts 
compared with these counts at 6, 12 and 18 months’  treatment on PI-based  
HAART regimens 
• HAART adherence levels as measured by regular clinical attendance 
• WHO developmental stage of AIDS 
• opportunistic infections 
• side-effects of ARVs reported by patients 
• deaths 
• reasons why patients were put on a specific 2nd line HAART regimen 
• patients’ periods of failing on the 1st line HAART regimen before being 
changed to the PI-based HAART regimen. 
• treatment outcomes of different PI-based regimens. 
 
1.5    SIGNIFICANCE OF THE STUDY 
 
This study could contribute to the body of literature comparing the efficacy of PI-
based HAART regimens and may be significant in the HIV/AIDS treatment and care 
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guidelines for Trinidad. The study could provide evidence of the efficacy of the PI-
based HAART regimens in Trinidad as well as evidence of the superiority of one PI-
based HAART regimen over the other in Trinidad. If the efficacy of PI-based HAART 
regimens is less than the acceptable standard, it might mean there could be a need 
for more NRTIs for first or second line patients in Trinidad.  A study such as this 
could identify a need for baseline resistance testing for patients before starting first 
or second line HAART.  
 
The laboratory results will determine if there is a correlation between the VL count, 
CD4 count and clinical outcome of specific patients.  
 
1.6    DEFINITIONS OF KEY TERMS 
 
HIV: Human immunodeficiency virus is the virus that causes AIDS (HIV 2013). 
 
AIDS: Acquired immune deficiency syndrome, caused by HIV, is a group of 
syndromes in humans caused by progressive failure of the immune system allowing 
life threatening opportunistic infections and cancer to thrive (Wikipedia 2013). 
 
CD4: This is the receptor site of the T lymphocytes to which the HIV particle attaches 
itself to enter the cell to replicate itself. The T lymphocyte dies at the end of the HIV 
life cycle. A measure of CD4 levels is used to assess disease progression and the 
patient’s response to treatment (Avert 2013).  
 
WHO stages: Some symptoms of HIV/AIDS are diarrhoea, weight loss, oral thrush, 
skin rashes, tuberculosis, and malignancies, and patients are grouped based on 
clinical presentation into stages 1, 2, 3 and 4, in increasing order of progression of 
the disease, as was explicated in table 1.1 of this dissertation ( WHO 2010: 27-28). 
. 
Viral Load (V) is a measure of the level of the virus in HIV infected patients. It is 
measured at six months post initiation of HAART and six monthly thereafter. The 
HIV/AIDs treatment and care guidelines of Trinidad and Tobago regard levels above 
1000 copies/ml as treatment failure (MOHTT 2009:9). 
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Anti-retroviral (ARV) drugs are drugs that reduce the level of HIV in the patient. 
Several different groups of ARVs are in use, each classified according to its 
mechanism of action.  
 
Highly active anti-retroviral treatment (HAART) is a treatment paradigm using 
three or more antiretroviral drugs in combination. First line HAART is the first group 
of drugs used by HIV patients who have never used ARVs before. In Trinidad and 
Tobago, patients who have previously used TDF and FTC with EFV or NVP are 
switched to AZT, 3TC and LPV/r. Those who used AZT and 3TC with EFV or NVP 
are switched to Truvada and LPV/r (MOHTT 2009:9). 
 
Immune reconstitution inflammatory syndrome (IRIS) usually occurs within the 
first six months of ART, in patients with very low CD4 counts at HAART initiation, 
and it is a paradoxical worsening of previously treated opportunistic infections (OIs) 
or the presentation of subclinical infections which are unmasked by the host’s 
regained capacity to counteract and overcome an inflammatory response (French 
2009:101). 
 
2nd line HAART treatment outcomes pertain to the independent variables which in 
this study are the PI-based HAART regimens. The dependent variable refers to the 
treatment outcomes of the regimen measured by CD4, VL, and the WHO clinical 
stage of the patient. 
  
2nd line HAART efficiency and inefficiency: A CD4 increase of at least 
50cells/mm3, after six months on second line HAART, will be regarded as indicating 
an acceptable efficacy, and a treatment success. Any drop in a patient’s CD4 count 
to 50% of peak value, or any drop up to or below baseline pre-initiation of PI-based 
HAART after six months on a PI-based HAART regimen, will be regarded as being 
treatment failure. A CD4 count remaining persistently below 100cells/mm3 after six 
months on PI-based HAART will also be regarded as being treatment failure 
(MOHTT 2009:9). Viral load (VL) above 1000 copies/ml, after six months on PI-
based HAART, will be considered as being an ineffective HAART outcome (MOHTT 
2009:9).  
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Clinical outcome will be assessed based on a change in disease progression 
evidenced by reported new opportunistic infections (OIs) or death, after being on PI-
based HAART for at least six months. The appropriate staging will be recorded at 
six, 12 and 18 months on PI-based HAART for each patient. Progression to a more 
severe stage, while on PI-based HAART, will be regarded as failure once it has been 
determined that it is not IRIS, by a closer examination of the patients’ record 
(MOHTT 2009:9).  
 
1.7    FOUNDATIONS OF THE STUDY 
 
No theoretical grounding will be used in this dissertation of limited scope, but the 
HIV/AIDS care and treatment guidelines of Trinidad and Tobago (MOHTT 2009) will 
be used as a basis for grounding this study. Some of the most important statements 
in this guideline which will be used as a guide for this study include: 
 
• The ARVs used for second line in Trinidad are completely unused NRTIs and 
PIs. Patients who have previously used TDF and FTC with EFV or NVP are 
switched to AZT, 3TC and LPV/r. Those who used AZT and 3TC with EFV or 
NVP are switched to Truvada and LPV/r (MOHTT 2009:9). 
 
• Definitions of failure on HAART will be accepted as outlined by the  WHO 
definitions for clinical, immunological and virological failure in an adherent 
patient who has been on HAART at least six months (MOHTT 2009:9-12): 
 
- Clinical failure will be indicated by a new or a recurrent stage 4 condition. 
 
- Immunological failure will be indicated by a fall of a patient’s CD4 count to 
or below baseline, or fall below 50% of on-treatment peak value or 
persistent CD4 values less than 100cells/mm3. 
 
 
- Virological failure will be indicated by a plasma viral load greater than 1000 
copies/ml and repeat viral load to confirm failure. 
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1.8    RESEARCH DESIGN AND METHOD 
 
This was a quantitative non-experimental cross sectional retrospective study. It was 
a descriptive correlational study. Quantitative research adopts the positivist paradigm 
of research. This approach is appropriate for this study as it assumes that there is a 
reality to be proven. In this study, a correlation between the independent and 
dependent variables were examined to compare the HAART treatment outcomes 
(dependent variable) of patients on PI-based second line HAART regimens 
(independent variable) in use in Trinidad (independent variable) (Dawson 2009:15; 
Morroni & Myer 2007:77-78; Polit,  Beck & Hungler 2001:169-186). 
 
This study was a non-experimental study because the patients could not be 
randomly assigned to any category of second line HAART. The patients, whose 
medical files were examined, were already on second line HAART regimens before 
the study commenced. Cross-sectional designs are especially appropriate for 
describing the status of phenomena or relationships among phenomena at a fixed 
point. This study is retrospective because it captures events occurring in the past, as 
reflected in the medical records of patients on second line HAART, as the 
independent variables. The dependent variables in this study were the clinical, 
virological (VL) and immunological (CD4) outcomes which were recorded at fixed 
points of 6, 12 and 18 months after commencing second line HAART regimens. A 
descriptive correlational study describes relationships among variables. In this study, 
the major aim was to compare the treatment outcomes of the second line HAART 
regimens by assessing the clinical (WHO staging), virological (VL) and 
immunological (CD4) outcomes (Dawson 2009:15; Morroni & Myer 2007:77-78; Polit 
et al 2001:169-186). 
 
The research methodology and design adopted throughout this study will be 
addressed in detail in chapter 3. 
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1.9   SCOPE OF THE STUDY 
 
This study was only conducted on the records of patients who had been on second 
line HAART regimens for at least six uninterrupted months at the SFGH in Trinidad. 
The findings at the SFGH may not be generalisable to patients on second line 
HAART in Trinidad and Tobago who receive ARVs at other centers. 
 
Patients on treatment for less than six months might encounter different challenges.  
Children and young persons (younger than 21 years of age) might experience 
different treatment outcomes from those experienced by older patients, but this fell 
beyond the scope of the current study. 
 
Errors in recording information are possible. Information extracted from patients’ 
records might have been inaccurately recorded. The checklists were carefully 
numbered and stapled together before starting with the data collection from any 
patient’s record to prevent errors of transcription of information. There are several 
confounders that might affect the efficacy of HAART regimens. This study included a 
detailed literature review.   
 
However, patients’ records with possible confounding variables such as cancer, TB 
or major surgery will not be excluded from the study, but will be analysed statistically 
and these issues will be addressed. ARV resistance is not determined in all patients 
of SFGH before starting regimens, and the possibility of multidrug resistant HIV 
strains could affect the efficacy of second line HAART regimens.  
 
However, the possibility of multidrug resistant HIV strains will be considered by the 
history of ARV drug usage as documented in the patients’ medical records. The 
possibility exists of patients’ false ARV use history, but the clinic attendances will be 
considered in this study and not the patients’ self-reported adherence levels (Myer & 
Karim 2007:155-167). 
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1.10    STRUCTURE OF THE DISSERTATION 
 
This dissertation has been written in five chapters as follows: 
 
Chapter 1 discusses the background to the research problem, aim of the study, 
significance of the study, definition of terms used in the study specifically the 
independent and dependent variables, foundation of the study, and a brief 
description of the research design.  
 
Chapter 2 reviews the literature on choosing second line HAART regimens, factors 
affecting efficacy of HAART regimens, and acceptable efficacy of second line 
HAART regimens. A model was designed by the researcher, based on the literature 
review, to contextualise the major aspects of this study. 
 
Chapter 3 describes in detail the research method used in data collection, quality 
control, confidentiality control methods and analysis of the data. 
 
Chapter 4 presents the data analysis and discussions. 
 
Chapter 5 documents the interpretation of the research findings, provides answers 
to the research questions and recommendations for further research and 
modification of HAART regimens in Trinidad. This chapter also specifies the 
limitations of this study. 
 
1.11 SUMMARY 
 
It has been highlighted in this chapter that there is a need for a study such as this, 
comparing the second line regimens in use in Trinidad. Critical questions that may 
be answered by this study include reasons why patients were placed on either of the 
second line HAART regimens of Trinidad, their adherence levels to these regimens, 
side effects reported on second line medications and efficacy of the regimens. The 
purpose, objectives, significance, study methodology and the scope as well as the 
limitations of the study were discussed.  
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The next chapter will discuss the literature reviewed about the efficacy of second line 
HAART studies and methods used to carry out such studies. This provides 
information that will be compared with the results of this study. 
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CHAPTER 2 
 
LITERATURE REVIEW 
 
 
2.1   INTRODUCTION 
 
This chapter discusses the literature review, addressing what is known about the 
efficacy of HAART regimens and the methodology used in carrying out the study. An 
understanding of HIV biology is necessary to understand the mechanisms of action of 
ARVs, the combination strategies and the efficacy of different HAART regimens.  
 
2.2   HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) 
 
In this section the biology and life cycle of the HIV will be discussed, followed by 
explaining how ARVs impact on the life cycle of the HIV. 
 
2.2.1   Biology and life cycle of HIV 
 
HIV is a microscopic organism, a virus, which destroys the body’s inherent ability to fight 
disease, leading to AIDS (Avert 2013). There are several classifications of HIV variants, 
the most common in Trinidad being HIV 1, Subtype B (CHART 2001). 
  
The virus has a circular shape. Its core ribonucleic acid (RNA) genetic material is 
covered by an envelope that has many small glycoprotein projections on its surface, the 
gp120 and gp41. These projections have an attraction to certain target cells with CD4 
receptor sites (Avert 2013). 
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The core (or capsid) of the virus is usually bullet shaped. This core contains enzymes 
required for viral replication, reverse transcriptase, integrase and protease and the 
genetic material, which consists of two identical strands of RNA (Avert 2013).  
 
 
                              
 
                                       
                                                       Figure 2.1 : HIV Structure 
                                                   (Source: http://www.avert.org/hiv-virus.htm) 
 
The HIV life cycle can be divided into a number of steps including succession, binding, 
fusion and entry, reverse transcription and integration, transcription and translation, then 
assembly, budding and maturation, which all take place in CD4 cells. The CD4 cell dies 
at the end of the cycle (Avert 2013). HIV principally affects CD4 T helper lymphocytes 
(TH cells). These TH cells are responsible for the initiation of nearly all immunological 
responses to pathogens, and following infection by HIV, there is attrition of the CD4 cell 
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population resulting in gradual and increasing failure of most aspects of immune 
function but particularly cell-mediated immunity, predisposing the body to OIs (Wilkins 
2010). Specific ARVs aim to inhibit fusion and entry, such as reverse transcriptase, 
integrase and protease enzymes (Wilson, Naidoo, Bekker, Cotton & Maartens 2002:19). 
 
2.2.2   Antiretroviral therapy (ART) 
 
ARVs are supplied free of charge to patients in Trinidad. Who gets ARVs in Trinidad is 
determined by the HIV/AIDS treatment and care guidelines, based on the WHO’s 
(2010:24) recommendations. The Trinidad HIV/AIDS treatment and care guidelines for 
adults and children recommend that all patients with CD4 counts of less than 
350cells/mm3 or with clinical staging from stage 3 upwards should commence ARVs 
(MOHTT 2009:5).  
 
ARVs are grouped according to their mechanisms of action. The mechanism of action is 
best understood against the background knowledge of the life cycle of HIV (addressed 
in section 2.2.1). The currently approved groups of ARVs by the United States Food and 
Drug Administration (FDA) are the NRTIs, NNRTIs, PIs, fusion inhibitors, entry 
inhibitors, and integrase inhibitors (FDA 2013). 
 
The NRTIs and NNRTIs inhibit the reverse transcriptase enzyme which is necessary for 
the HIV life cycle’s developmental step of reverse transcription. In Trinidad, available 
NRTIs include d4T, 3TC, AZT, abacavir (ABC), didanosine (ddI), FTC and TDF. 
Truvada is a combination of TDF and FTC, and combivir is a combination of 3TC and 
AZT. The most notable class wide adverse effect of NRTIs is mitochondrial toxicity, 
which is responsible for the clinical syndromes of lactic acidosis with hepatic steatosis, 
peripheral neuropathy, and lipo-atrophy. Lamivudine, ABC, TDF and FTC are the NRTIs 
with low mitochondrial toxicity potential. The NNRTI group includes four approved drugs 
which are NVP, EFV, delavirdine, rilpivirine and etravirine. NVP and EFV are available 
in Trinidad. The most notable side effect associated with all NNRTIs is a rash which 
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usually occurs within the first six weeks of initiation of therapy and has been noted in up 
to 35% of patients receiving this treatment. NVP is also associated with hepatotoxicity, 
particularly in women with CD4 above 250cells/mm3 and men with CD4 counts above 
400 cells/mm3 (MOHTT 2009:52). 
 
PIs inhibit the protease enzyme responsible for the final cleavage of large viral 
precursor polypeptide chains into smaller, functional proteins, preventing maturation of 
the HIV virion (Wilson et al 2002). This results in the release of structurally disorganised 
and non-infectious viral particles. The FDA’s currently approved PIs are fosamprenavir 
(FOS-APV), atazanavir (ATZ), darunavir (DRV), indinavir (IDV), lopinavir (LPV), 
nelfinavir (NFV), ritonavir (RTV/r), saquinavir (SQV), and tipranavir (TPV) (FDA 2013). 
Drug interactions are important considerations with the use of PIs. The PIs are 
substrates for the cytochrome P450 system in the liver and they also inhibit as well as 
induce this enzyme system to varying degrees, with RTV being the most potent 
inhibitor. This can cause a considerable number of interactions with drugs that are 
inducers, inhibitors, or substrates of this system. Three PIs (LPV, TPV and DRV) 
require co-administration with RTV to achieve effective serum concentrations. PIs 
available in Trinidad include ritonavir boosted lopinavir LPV/r, RTV, SQV, IDV, ATV and 
NFV (MOHTT 2009:52). The side effects of PIs include nausea, diarrhoea and vomiting. 
ATZ specifically causes skin rashes, and IDV could cause kidney stones (MOHTT 
2009:52). 
 
Entry Inhibitors and integrase inhibitors were not available for use in Trinidad (MOHTT 
2009:52) when this study was conducted.  
 
2.3   THE EFFICACY OF HAART REGIMENS 
 
Antiretroviral regimens are modified for four reasons: toxicity, intolerance, treatment 
failure and evidence showing superiority of a different regimen. Switching from first-line 
to second line regimens is most frequently done in Trinidad in response to treatment 
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failure, and sometimes toxicity of prior regimens. Treatment failure can be assessed in 
three ways: clinically by disease progression and WHO staging, immunologically by 
CD4 trends over time and virologically by measuring the VL (MOHTT 2009:9).  
 
Clinical failure is defined as new or recurrent WHO stage 4 conditions, and certain stage 
3 conditions, including serious bacterial infections and tuberculosis.  These conditions 
must be differentiated from IRIS, which normally occurs in the first six months following 
HAART and is a re-activation of a previously latent infection, or exacerbation of treated 
opportunistic infections (OIs) (MOHTT 2009:8-9). Immunological failure is defined in the 
Trinidad guidelines as well as the WHO guidelines, as a fall in CD4 counts to levels at 
or below pre therapy baseline levels or a 50% fall from the on-treatment peak value, or 
CD4 levels persistently lower than 100cells/mm3 after 24 weeks on treatment, all in the 
absence of concomitant infection to cause transient CD4 cell decrease (MOHTT 
2009:8-9). In Trinidad, CD4 levels are done at baseline, after three months on HAART, 
and at six months, and subsequently six monthly (MOHTT 2009:8-9). Virological failure 
is defined in the Trinidad guidelines as failure to achieve VL of less than 1000 copies/ml 
by 24 weeks in an adherent patient (MOHTT 2009:8-9). The WHO guidelines define 
virological failure as persistent plasma VL above 5000 copies/ml. VL levels must be 
correlated with clinical and immunological findings. The WHO recommends confirmation 
of treatment failure by viral load measurement. The WHO emphasises that switching of 
ARV regimens for treatment failure should only be considered when clinical and 
immunological criteria are used to confirm treatment failure (WHO 2010:48-52). 
 
Before switching regimens due to treatment failure, non adherence, which is the most 
frequent cause of treatment failure, must be ruled out. Adherence counseling must be 
done and adherence readiness must be assured. When treatment failure is suspected, 
CD4 and VL are repeated after three months, and attempts should be made to identify 
and correct the cause(s) of treatment failure (MOHTT 2009:12).  
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Apart from non-adherence, there are several confounding variables that could affect the 
CD4 and VL levels as well as the clinical presentation of patients.  According to Lab 
Tests Online (2012:1), CD4 counts can be influenced by analytical variations from the 
laboratory, seasonal and diurnal changes, with the lowest at 12.30pm and highest at 
8.30pm. Gallant and Hoffman (2009) have elaborated that several variables can affect 
CD4 and VL levels in their article on CD4 count. Modest decreases in CD4 cell counts 
have been noted with some acute infections and with major surgery. Corticosteroid 
administration and interferon treatment cause severe decreases in CD4 cell counts. 
Medical conditions associated with low CD4 counts include Sjogren syndrome, 
sarcoidosis, radiation, atopic dermatitis, collagen-vascular disease, lymphoma, stem cell 
transplant recipients and idiopathic CD4 lymphopaenia. Acute changes are probably 
due to redistribution of leukocytes between the peripheral circulation and the marrow, 
spleen, and lymph nodes. Baseline CD4 also affects the increases in levels seen while 
on ART. Concurrent Human T-cell Leukaemia Virus Type 1 (HTLV-1) infection and 
splenectomy may lead to deceptively high CD4 levels. Gender, race, age in adults, risk 
category, psychological stress, physical stress and pregnancy have minimal effects on 
CD4 counts. Pregnancy leads to hemo-dilution and a small decline in CD4 count, but no 
decline in CD4%. Lab Tests Online (2012:1) state that due to the normal variability of 
CD4 cells, the number of CD4 cells can be compared to other types of lymphocytes. 
When compared to CD8 count, it is expressed as CD4/CD8 ratio and when compared to 
the total lymphocyte count, it is expressed as CD4%.  Deciding if a CD4 level change is 
true and not a normal variation is made by comparing the CD4/CD8 ratios and CD4% 
which are relatively constant.  Wilson et al (2002:47) stated that in HIV-negative 
individuals, the CD4 is slightly higher than the CD8 and the CD4/CD8 ratio is slightly 
above 1. When there is a true drop in CD4 levels, the CD4/CD8 ratio falls but in normal 
variation in HIV negative persons, the CD8 swings with CD4 levels and the ratio of 
CD4/CD8 is almost constant. This will be taken into consideration when deciding 
whether or not the patients in the study sample failed to respond to their regimens. Viral 
loads (VL) can be abnormally high following immunisation, acute illnesses and surgical 
procedures or hospitalisation (Gallant & Hoffman 2009). The clinical syndrome of IRIS 
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must be differentiated from new OIs, as IRIS occurs in patients with very low CD4 
counts at HAART initiation, within the first six months of ART (MOHTT 2009:8-9). The 
first line regimen is given at least six months’ time to detect immunological and 
virological improvements before considering switching to second line HAART. This 
research will identify whether or not confounding variables were present at the time of 
blood tests used to monitor the efficacy of second line regimens. 
  
2.4   FACTORS AFFECTING THE EFFICACY OF HAART 
 
The aim of ART is to make the amount of HIV in the body very low, preventing or 
reversing damage to the immune system, and preventing illness or restoring health to 
HIV-positive patients. Drug resistance is the inevitable consequence of incomplete 
suppression of HIV-1 replication, which depends on the efficacy of the regimen being 
used. Multiple factors influence the development of HIV drug resistance, including the 
biology of HIV, genetic barriers of ARVs to resistance, regimen potency, 
pharmacokinetics of ARVs, and medication adherence (Demeter, Bartlett & McGovern 
2008). 
 
● HIV Biology 
 
Many drug resistant variants of HIV, which usually replicate less efficiently than drug- 
sensitive strains in the absence of specific drugs, are thought to pre-exist at low levels 
before drug therapy is initiated. A study in North Carolina, in the United States of 
America, revealed that there is high prevalence of transmitted resistance in newly 
diagnosed HIV-positive patients (Youmans, Tripathi, Albrecht, Gibson & Duffus 2011). A 
2003 study in the Caribbean in Barbados uncovered a single viral strain that harboured 
resistance to ZDV, Zalcitabine (ddC) and ddI (CHART 2001). If virus replication is not 
fully suppressed by the ART regimen, these mutants can either cause overt virological 
failure, or, if replication in the presence of drugs persists, become more drug-resistant 
by the gradual accumulation of additional resistant mutations (Demeter et al 2008).  
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Sporadic observations have also shown changing patterns of transmitted drug resistant 
mutations in HIV infection even without selection pressure of ART (Reuter, Oette, 
Sichtig, Kaise, Balduin, Jensen & Häussinger 2011:188). 
 
● Genetic barriers to resistance 
 
HIV can develop high-level resistance to some drugs with only a single mutation, while 
other drugs require multiple mutations of the virus for the virus to become resistant to 
antiviral drugs’ activities. The former drugs are referred to as having a ‘’low genetic 
barrier’’ to resistance and the latter, a ‘’high genetic barrier’’. Lamivudine, FTC, NVP and 
EFV have low genetic barriers. PIs have a high genetic barrier to resistance (Demeter et 
al 2008). Of treatment-experienced patients who failed a first line HAART regimen in 
South Africa, 80% had ARV-resistant virus which reflected the types of drugs used in 
the first- line regimens, and the viral subtypes (Marconi, Sunpath, Gordon, Koranteng-
Apeagyei, Hampton, Carpenter, Giddy, Ross, Holst, Losina, Walker & Kuritzkes 
2008:1590). 
 
● Regimen potency 
 
The potency of an individual drug or a combination of drugs is a crucial determinant of 
VL suppression. If the VL is not fully suppressed, continued virus replication in the 
presence of a drug can lead to the accumulation of mutations, leading to the 
development of virus resistance, even to drugs with a high genetic barrier to resistance. 
This research is about determining the most potent PI-based second line regimens in 
use in Trinidad, as well as the efficacy of each individual regimen (Demeter et al 2008; 
WHO 2010: 55-56). 
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● Pharmacokinetics 
 
Sub-therapeutic levels of ARVs can be caused by low concentrations, adverse drug 
interactions as well as monotherapy. Low serum concentrations could pose problems 
for PIs, but could be offset by the use of pharmacokinetic ‘’boosting’’ with RTV. Use of 
certain medications, concurrently with ARVs, can reduce serum concentrations of the 
drug such as the use of Rifampicin (an anti-TB medication) which is contra-indicated for 
combinations with both NVP and LPV/r because it reduces the serum concentration of 
these drugs by 20-58% and 75% respectively. A thorough understanding of these 
interactions is necessary for clinicians who prescribe ARVs (WHO 2010:46). 
 
● Medication adherence 
 
It has been proposed that the relationship between adherence and drug resistance is 
complex and influenced by drug potency and pharmacokinetics (WHO 2010:70). A 
study by Alcorn and Thaczuk (2008) in British Columbia showed that adherence levels 
exceeding 95% are necessary to maximise the benefits of ART. In a study in China, 
patients with detected viraemias had increasing prevalence of NRTI and NNRTI- 
resistant mutations within months of being on therapy (24.3% at 3-6 months, 57.1% at 
9-12 months and 63.3% at 20-24 months) which were attributed to low levels of 
adherence to ARVs (Luo, Liu, Zhuang, Lui, Su, Yang, Tien, Zhang, Gui & Chen 2009).  
  
Based on the literature review and on the researcher’s experience of treating PLWA/H, 
a model was designed to portray the factors affecting the efficacy of second line HAART 
regimens and the possible outcomes of second line HAART uninterrupted therapy for at 
least six months.  
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Figure  2.2:   Conceptual model of factors affecting the efficacy of second line HAART 
regimens and possible outcomes of second line HAART uninterrupted therapy for at 
least six months.  
On first-line HAART 
at least 6 months at least 6 onths 
Treatment failure     
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                   • persistently 
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2.5   COMPARING THE EFFICACY OF DIFFERENT HAART REGIMENS 
 
In choosing NRTI backbones, clinicians should consider what should be reserved for 
the second line NRTI backbone. Knowledge of the resistance patterns developed in 
response to first line ARVs is employed in choosing regimens to use as second line 
ART regimens. In supporting this statement, the WHO (2010:53-57) also states that a 
new second line regimen has to involve drugs that retain their activity against the 
patients’ virus strain and should ideally include a minimum of three active drugs, one of 
them from at least one new class, in order to increase the likelihood of treatment 
success and minimise the risk of cross resistance. The WHO recommends that the PI 
class should be reserved for use in the second line regimen in combination with two 
unused NRTIs. Medecins Sans Frontieres (MSF) documented favourable outcomes in 
protease inhibitor-based second line regimens with at least one NRTI change (Pujades-
Rodríguez et al 2008:1305-1312). The PI of choice in Trinidad is the RTV boosted LPV, 
LPV/r. Patients who have previously used TDF/FTC/EFV or NVP are switched to 
AZT/3TC/LPV/r. Those who used AZT/ 3TC/EFV or NVP are switched to 
TDF/FTC/LPV/r (MOHTT 2009:10).  
 
The WHO (2010:53) states that few studies were identified in a systematic review 
conducted with the objective of assessing the optimum second line ART regimen in 
patients failing first line therapy, in resource limited settings. 
 
There is cross resistance between 3TC and FTC. The WHO (2012:11) stated that these 
two drugs are similar in activity, and can be used interchangeably. Studies proving the 
efficacy of using either drug after the other had failed in a previous regimen could not be 
identified. M184V mutation is developed against 3TC and FTC. The continued use of 
3TC or FTC in second line ART regimens is recommended by some experts because 
they maintain the M184V mutation which confers a viral replication defect (Wei, Liang, 
Götte & Wainberg  2002:2392) or may possess residual antiviral activity (Highleyman 
2009). Maintaining the M184V mutation is also thought to improve sensitisation of the 
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virus to AZT, d4T and TDF. A study in British Columbia, Canada, by Hull et al 
demonstrated that  amongst individuals with documented M184V mutations, with or 
without additional NNRTI resistance, standard three - drug  boosted PI-based regimens 
containing 3TC “appeared equally effective’’ at achieving virological suppression 
compared with more intensive multi-drug combinations or 3TC-sparing regimens 
(Highleyman 2009). Patients taking 3TC or FTC plus another NRTI and a PI were as 
likely to achieve undetectable viral load as those with completely unused NRTIs 
(Pujades-Rodríguez et al 2008:1305-1312).  The patients in the present study were 
presumed to have developed M184V mutation to 3TC or FTC on the first line regimens 
in use in Trinidad (MOHTT 2009: 9).  
 
In Guyana, the preferred first line regimen is TDF/FTC/EVF. There are two second line 
regimens in use in Guyana, 2a and 2b which both use TDF/FTC as the NRTI 
backbones, the same as is used in the first line regimens, with PI, LPV/r. The 2b 
regimen has AZT added to the NRTI backbone.  After failure of the first line ART 
regimen containing 3TC or FTC, combinations of 3TC or FTC and AZT with TDF are 
thought to provide retained activity of AZT and TDF, while reducing viral fitness and 
replication (MOHG 2010/2011). There was no documented study done in Guyana to 
prove the clinical efficacy of this strategy. In a study done in India using the same 
second-line HAART regimens as in Guyana, there was no significant difference in the 
efficacy of the two regimens. However, all the patients in the study in India used AZT 
and 3TC in their first line regimen with EFV or NVP (Guha, Bhandari, Pain, Saha, 
Goswami & Ray 2011). If there was any significant difference, it might be relevant in 
choosing second-line regimens in Trinidad. A few patients in Trinidad use a similar 
regimen as the 2b regimen in Guyana when the prior ARV history suggested this to be 
the appropriate combination. 
 
All NRTI have in common the K65R mutation developing when regimens fail.  AZT is 
thought to delay the emergence of K65R mutation which usually confers resistance to 
TDF. Thymidine analogue mutations (TAMs) are developed to AZT and d4T. In vitro 
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studies demonstrate that K65R and TAMs are rarely detected in the same plasma 
sample. Such studies demonstrate that the introduction of K65R into recombinant 
viruses containing TAMs reduced AZT resistance from over 50-fold to less than 
threefold. In contrast, the presence of TAMs decreases the likelihood of K65R selection. 
Findings such as this may imply that the use of AZT in combination with 3TC and an 
NNRTI, as a first line regimen, may preserve TDF for use in second-line regimens, 
when it would be a completely unused ARV and development of K65R is prevented by 
TAMS which have occurred in the first line regimen, to AZT.  Then AZT resistance due 
to the development of TAMs would be reduced significantly by the introduction of TDF 
and continuance of FTC. The function of FTC, as antiviral in this case, would be 
negligible because of the high level of resistance conferred by M184V to FTC and 3TC, 
but also advantageous in increasing susceptibility to AZT and TDF. Using AZT in the 
first ART regimen might prolong the first line regimen because it has a high genetic 
barrier to resistance, and at least three TAMs are required before all virologic activity of 
AZT is completely lost. Noteworthy is the potential for AZT to cause anaemia.  
 
The TDF/FTC combination has the advantage of minimal side effects of the 
combination, and a once daily dosing regimen, making the patients’ lives easier and 
probably enhancing ART adherence levels. An alternative would be to continue using 
d4T/3TC/NNRTI as first line regimen, then switch to TDF/AZT/FTCPI as second-line, 
and in this way, TDF and AZT would be completely new drugs reserved for second-line. 
But d4T causes unfavourable side-effects of dyslipidaemia, lactic acidosis and/or 
pancreatitis and peripheral neuropathy (Bartlett, Hirsch & McGovern 2008; Cohen, 
Gallant, Bartlett & McGovern 2008).  
 
In a study in Cambodia, a high efficacy of LPV/r second-line ARV regimen was 
achieved (Ferradini, Ouk, Segeral, Nouhin, Dulioust, Hak, Fournier, Lerolle, Ngin, Mean, 
Delfraissy & Nerrienet 2011). However, a combined efficacy of four different regimens 
was used in that study which compared regimens of didanosine (ddI)/3TC/LPV/r 
(65.7%), ddI/TDF/LPV/r (10.0%), ddI/AZT/LPV/r (8.6%) and TDF/3TC/LPV/r (7.1%). 
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Another study in South Africa showed high rates of survival, immune reconstitution and 
virologic suppression in patients on second-line HAART using ddI/AZT/LPV/r (Fox, Ive, 
Long, Maskew & Sanne  2010).  
 
2.6   METHODOLOGIES USED IN STUDIES THAT COMPARED HAART REGIMENS 
 
Several methods have been used by previous researchers to evaluate second-line 
HAART efficacy including observational cohort and case control methods, randomised 
controlled trials, systematic reviews and meta-analysis. The WHO used a standard 
Cochrane review method, including several studies that adopted these methods, to 
carry out a meta-analysis to gather data before making its current recommendations in 
2010. Ferradini et al (2011:14) studied second-line regimen efficacy in Cambodia 
retrospectively by analysing their immune-virological data at a fixed point. In the study in 
India by Guha et al (2011), a retrospective patients’ chart review was done. This is the 
same method that was used in the current study. 
 
2.7    CONCLUSION 
 
There is an urgent need for research to determine the efficacy of second-line HAART 
regimens currently recommended by the WHO. Clinicians could use this information for 
choosing future regimens to enhance their patients’ treatment outcomes and to make 
cost-effective clinical decisions. 
 
In this study, PI containing second-line regimens AZT/3TC/LPV/r and TDF/FTC/LPV/r 
were the major HAART regimens being studied. However, some other regimens 
containing PIs are also being used at the center. The data were also extracted for these 
regimens and analysed.  The next chapter will present the research method and design 
adopted by this study. 
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CHAPTER 3 
 
RESEARCH DESIGN AND METHOD 
 
3.1   INTRODUCTION 
 
In this chapter, the methodology that was used in the study is explained. The research 
design and method, sampling, data collection and analysis and ethical considerations 
are addressed in this chapter. It was a quantitative study and the data were extracted 
from the records of patients by the researcher using self-designed checklists. 
 
3.2   RESEARCH DESIGN 
 
 A research design is an overall plan for addressing a research question and it includes 
a description of what has been done to enhance the integrity of the study.  This was a 
quantitative non-experimental cross sectional retrospective survey. It was a descriptive 
correlational study, comparing the treatment outcomes of patients on HAART regimens 
containing PIs (second line ART).  
 
This study was a non-experimental study because the patients could not be randomly 
assigned to any category of HAART. The patients, whose medical files were examined, 
were already on PI-based HAART regimens before the study commenced. Cross-
sectional designs are especially appropriate for describing the status of phenomena or 
relationships among phenomena at a fixed point (Polit et al 2001:169-186, 470). This 
study is retrospective because it captures events occurring in the past, as reflected in 
the medical records of patients on PI-based HAART regimens in Trinidad, as the 
independent variables. The dependent variables in this study were the clinical 
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(WHO staging), virological (VL) and immunological (CD4) outcomes which were 
recorded at fixed points of 6, 12 and 18 months after commencing PI-based HAART 
regimens. A descriptive correlational study describes relationships among variables. In 
this research, the major aim was to compare the treatment outcomes of the PI-based 
HAART regimens by the clinical (WHO staging), virological (VL) and immunological 
(CD4) outcomes (Dawson 2009:15; Morroni & Myer 2007:77-78). 
 
3.3    RESEARCH METHOD 
 
The research method indicates the steps, procedures and strategies for gathering and 
analysing data in a research investigation. The population, sampling method and 
sample will be described in this section of the dissertation, as well as the research 
instrument and the data gathering process (Polit et al 2001:465). 
 
3.3.1   Population 
 
A study population is defined as any universe of subjects, cases, units or observations 
(Stommel & Wills 2004:441). A population comprises “… all elements, including 
individuals, objects, events, or substances that meet the sample criteria for inclusion in 
a  study, sometimes referred to as a target population” (Burns & Grove 2009:714).  At 
the SFGH HIV clinic, 59 patients aged 21 and older had been on PI-based HAART 
regimens for at least six months by 31 August 2013 (SFGH records 2013). All 59 
patients, on PI-based HAART for at least six months by 31 August 2013, and who were 
21 years old or older, comprised the target population for this study. 
 
3.3.2   Sampling method and sample 
 
Sampling is the process by which a predetermined number of observations or persons 
are selected from a larger population to participate in a study. “Sampling theory 
determines mathematically the most effective way to acquire a sample that would 
accurately reflect the population under study.  The key concepts of sampling theory are 
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population, elements, sampling criteria, representativeness, sampling errors, 
randomisation, sampling frame and sampling plan” (Burns & Grove 2009:343). The 
sample is representative of the population if a random sample has been selected.  In 
random sampling, “… each member of the population has a probability greater than 
zero of being selected for a study” (Burns & Grove 2001:40).  
 
In this study, the 2013 records of the SFGH HIV clinic did not indicate which patients 
had been on PI-based HAART regimens for at least six months by 31 August 2013, and 
who were 21 years old or older. A manual count of all the records was done and the 
patients were categorised into four groups; not on ART, on NNRTI based ART, on PI-
based ART and salvage regimens. The patients in each group were further sub-
classified into active and inactive subgroups. Inactive patients were those not on 
HAART who had not been to the clinic for six months or longer; those on HAART who 
did not have ARVs to cover the period up to three months after their last prescribed 
medications should have been finished. Active patients were those who kept to their 
clinic appointments and whose records of prescribed ART were sufficient to cover the 
periods of absence from the clinics. The inclusion criteria were active patients over the 
age of 21 on PI-based regimens at least six months at the time of data collection. Data 
were extracted from all patients’ records that fit into the criteria.  A total of 59 patients 
were included in the study during data collection, but during analysis, due to missing 
data, only 35 patients’ data were included. The exclusion criteria stipulated that patients 
who had no baseline CD4 and no CD4 value at six months could not be included in the 
current study.  
 
3.3.2.1   Data collection approach and method 
 
Data were collected using a self designed checklist (Annexure 1) to extract data from 
the records of patients included in this research. 
 
 
 
33 
 
 
3.3.2.2   Development and testing of the data collection instrument 
 
The data collection instruments were designed after the literature review of studies, 
which identified several factors that affect HAART efficacy including confounders. A pre-
test was done by using the checklist to extract data from ten records by two different 
persons and then the data were extracted again from the same ten patients’ records by 
the researcher, and the information gathered by two people was compared to identify 
any discrepancies. The different records were identical and no discrepancies were 
detected. 
 
3.3.2.3    Characteristics of the data collection instruments 
 
The quality of the data collection instrument was assured by assessing the reliability 
and validity of the self designed checklist. 
 
• Reliability 
 
Three aspects of reliability are of interest to researchers collecting quantitative data: 
stability, internal consistency, and equivalence.  
 
Stability is a measure of the extent to which the same scores are obtained when the 
instrument is used with the same sample on separate occasions. This is derived 
through test-retest reliability procedures. The checklist was pretested as elaborated in 
section 3.3.2.3.The result for the two sets of 10 records was compared (Polit et al 2001: 
303-312) and no discrepancies were found. 
 
An instrument is said to have internal consistency to the extent that all its subparts 
measure the same characteristic. This was applied in creating the checklist by grouping 
the questions under five sections: demographic and medical information, HAART 
history, counselling and adherence information, second-line treatment history and side- 
effects. The Cronbach alpha coefficient could not be calculated for this study because 
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the large number of missing values from the patients’ records would have produced 
negative values (Polit et al 2001: 303-312). 
 
Equivalence determines the consistency or equivalence of the instruments by different 
observers. This did not apply to this research (Polit et al 2001: 303-312). 
 
• Validity 
 
 
Validity of measuring instruments is the degree to which an instrument measures what it 
is supposed to be measuring. There are several aspects of validity of instruments: face 
validity, content validity, criterion-related validity, and construct validity.  
 
Content validity is concerned with the adequacy of coverage of the content area being 
measured. Content validity is based on the fact that the researcher is an experienced 
HIV clinician who has done a detailed literature review before creating the checklist. 
Four other doctors working in the HAART field determined the relevance of every item 
in the checklist for identifying differences in the outcomes of the two groups of patients 
(Polit et al 2001: 303-312; (Validity in Research Design 2009). 
 
Construct validity refers to the testing of relationships predicted on the basis of 
theoretical considerations. In this research, patients who are adherent to second line 
HAART are expected to have increased CD4 and reduced VL and an improvement in 
their clinical staging of the disease (Validity in Research Design 2009).  
 
3.3.2.4   Data collection process 
 
Information was transcribed from patients’ records using checklists. A list of patients’ 
records included in this study was compiled, indicating each patient’s file number and 
the corresponding completed checklist’s number.   
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3.3.2.5   Ethical considerations related to data collection 
 
The list comprising each patient’s file number and checklist number was locked up in 
the office of the head of department for HIV/AIDS care and only the researcher had 
access to this list, in case the healthcare authorities or research authorities should 
require audits of the recorded data.  This list would be destroyed subsequent to the 
acceptance of the research report. The completed checklists were anonymous, only 
indicating each respondent’s checklist number (Polit et al 2001:75-83). 
 
3.3.3   Data analysis 
 
A statistician assisted with the data analysis and interpretation. Descriptive statistics 
were used for describing the respondents’ demographic characteristics and to measure 
associations using SPSS version 20. Associations between CD4 change percent and 
several variables were determined using chi-squares. The p-value was set at <0.05 for 
statistical significance (Joubert 2007:141-151).   
 
3.4   INTERNAL AND EXTERNAL VALIDITY OF THE STUDY 
 
The adequacy of a research design could be evaluated by an assessment of its internal 
and external validity. 
 
• Internal validity 
 
Internal validity refers to the extent to which it is possible to make an inference that the 
independent variable (PI-based HAART regimen) is truly influencing the dependent 
variables (CD4, VL, side effects, OIs). Threats to internal validity could be posed by the 
patient’s history, selection, maturation or mortality (Validity in Research Design 2009).  
 
The history threat is the occurrence of events concurrently with the independent 
variable that can affect the dependent variable. Several variables affect the efficacy of 
HAART, apart from the regimen potency, including adherence to HAART medications, 
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baseline CD4 and VL, presence of OIs, acute illnesses, major surgery and interactions 
with other medications. In records where there were unacceptable levels of CD4 or VL 
counts, a thorough re-examination of the records was done to determine whether any 
confounding variables were present at the time of the laboratory analysis. Any other 
factors (such as suffering from cancer or tuberculosis, using corticosteroids or 
interferon, major surgery and records of counseling sessions) identified in the patients’ 
records that might influence the HAART outcomes, were recorded on the checklist and 
indicated in the presentation and discussion of the research findings (Polit et al 
2001:193).  
 
Inclusion and exclusion criteria are a means of establishing precision in a study. 
Inclusion criteria are the criteria for including a patient in a study. Exclusion criteria are 
the criteria for excluding patients from the study. The inclusion criteria for the PI-based 
HAART regimens patients’ records are patients aged at least 21, on a PI-based HAART 
regimen for at least six uninterrupted months, with baseline and 6 months after 
treatment CD4 and VL results recorded in their files. The patients’ records were 
excluded if they had not been on PI-based HAART for at least six uninterrupted months 
or if they were younger than 21 years of age, or if they did not have baseline CD4 and 
VL results or if these results were not recorded 6 months after they had commenced PI-
based HAART.   
 
A selection threat encompasses biases resulting from pre-existing differences between 
groups, and might arise if respondents are not assigned randomly to groups. CD4 cell 
recovery has been related to the age of patients, younger patients are known to have a 
faster CD4 recovery. CD4 cell recovery is also related to basal CD4 cell counts. During 
the analysis of data, patients’ CD4 cell counts change percentages were stratified by 
age and baseline CD4 quartiles for the different groups of PI-based HAART regimen 
patients (Myer & Karim 2007; Polit et al 2001:187-195). 
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The threat of maturation arises from processes occurring within the subjects as a result 
of time rather than from the independent variable. In HIV-positive patients, without 
HAART, CD4 drops over time, while the VL rises. It is expected that the opposite will be 
the case in the research population on second line HAART regimens as long as they 
are adherent to their medications. Having a recorded trend of increasing CD4 and 
reducing VL in the patients’ files, could indicate that they were adherent to HAART. 
Falsely elevated CD4 counts, as seen in HTLV-1could not be controlled because the 
HTLV-1 serology of the patients were analysed at the participating healthcare facility but 
it was not exactly clear at what point in their care they had that investigation done. 
Splenectomies, which can increase patients’ CD4 counts falsely, would be recorded on 
the checklists (Polit et al 2001:187-195) if recorded on the patients’ files. 
  
Threats of mortality arise from differential attrition rates from the different groups of 
patients on different PI-based HAART regimens. Patients’ records were used, and only 
those who had been on PI-based HAART for at least six uninterrupted months were 
studied. Consequently, attrition and mortality were not expected to impact on this study.  
However, the availability and accessibility of patients’ records, as well as the 
completeness and accuracy of these records, might have influenced the data collection 
procedure in unpredictable ways (Polit et al 2001:187-195). 
 
• External validity 
 
External validity refers to the extent to which the research results can be generalised 
beyond the sample. The records of all patients at the centre who fit the inclusion criteria 
were included in the study. The results of this study will only be relevant for patients 
who had been on PI-based HAART regimens in Trinidad for at least six uninterrupted 
months by 31 August 2013 (Polit et al 2001:187-195). 
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Possible confounding variables that might impact on patients’ VL and CD4 counts were 
identified and discussed, such as TB, cancer, major surgery, splenectomy, recent 
immunisations and pregnancy.   
 
 
3.4    ETHICAL CONSIDERATIONS  
 
The research proposal was submitted to the Higher Degrees Committee of the 
Department of Health Studies, University of South Africa.  After the proposal had been 
revised, it was accepted by this committee and an ethical clearance letter was issued 
(see Annexure 2). 
 
Permission was obtained from the ethics committee of the SFGH before carrying out 
this research (see Annexure 3). The manager of the participating health facilities were 
informed about the study and about the permission obtained to collect data.  Each 
manager then granted permission for the researcher to collect data from the patients’ 
records. No human data sources were used in this research. Only medical records of 
patients aged 21 and older were used to collect data by means of completing self-
designed checklists. There were no risks for the patients.  
 
3.5   SUMMARY 
 
The method used to design the study, sampling, data collection and analysis and the 
existence of threats to the validity of the study, as well as several confounders have 
been investigated in this chapter.   
 
The next chapter will present the analysis and discussion of the data obtained during 
the analysis of the information transcribed from the patients’ records. 
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CHAPTER 4 
ANALYSIS, PRESENTATION AND DESCRIPTION OF 
RESEARCH FINDINGS 
 
4.1   INTRODUCTION 
 
This chapter presents and discusses the findings of this study.  Where relevant, these 
results will be compared with those of other studies. 
 
4.2    DATA MANAGEMENT AND ANALYSIS 
 
Checklists were completed from the records of patients attending the HIV clinic of the 
SFGH.  As many as 15 PI-based regimens were in use in the SFGH (see table 1.2). 
There was no immediately available method of identifying patients who fit the inclusion 
criteria of this study. A manual count of medical records was done and a total of 1 212 
medical records were available. The patients’ records were classified into four groups, 
namely those:  
 
• not on ART (n=289; 23.8%) 
• on NNRTI-based ART (n=669; 55.1%) 
• on PI-based ART (n=245; 20.2%) and  
• on salvage regimens (n=9; 0.7%).  
 
Each category was classified into two groups: active or inactive. Inactive patients were 
those not on HAART or who had not been to the clinic during the preceding six months.  
For those on HAART, inactive patients did not have ARVs to cover the period up to 
three months after their last prescribed medications should have been finished. Active 
patients were those who kept their clinic appointments and whose records of prescribed 
ARVs were sufficient to cover the periods of absence from the clinics. 
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A total of 164 patients were active on PI-based regimens and 15 different PI-based 
regimens were in use, as indicated in table 1.2. The PI-based regimen in current use 
was recorded as each patient’s current regimen and the date when that regimen was 
started was taken as the baseline for that patient. The CD4 and VL, taken just before 
the start of the current PI-based regimen, were taken as baseline values. There were a 
total of 59 patients on their current PI-based regimens for at least six months, who were 
at least 21years of age. However, during data analysis, due to missing data, only 35 
patients’ data were included (N=35) and they comprised the population of this study. 
 
All 35 patients had previously used ARVs before their current PI-based regimens. Some 
patients were switched to the current PI-based regimens after using NNRTI-based 
regimens containing two NRTIs and one NNRTI.  Some had used both NNRTI-based 
and PI-based regimens before starting the current regimen. Patients were switched to 
the current PI-based regimens for reasons such as failure of prior first line NNRTI-based 
regimens, toxicity to previous NNRTI-based regimens or PI-based regimens, to reduce 
pill burden of prior PI-based regimens, pregnancy and tuberculosis. Some were 
transferred from other health care facilities, when they were already on their PI-based 
regimens and for uncertain reasons (as stated on the patients’ files). Baseline and six 
months on treatment CD4 and VL values were extracted.  Only the CD4 counts at six 
months were used because that was the month with the least missing values for all 
patients who fit the inclusion criteria. Patients’ records without baseline CD4 and without 
CD4 values at six months were excluded from this study. 
 
The CD4 change percent was recorded for all patients and the relationship with the 
independent variables were inferred by using SPSS version 20.The CD4 change 
percent was computed, using SPSS, by the following equation: 
 
                                          6months CD4-Baseline CD4                  X 100 
                                                      Baseline CD4 
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CD4 has a normal variability (Lab Tests Online 2012:1) and a wide range of normal 
values, and the CD4/CD8 ratio might have been more appropriate to compare CD4 
levels between different records. However, this was impossible during the current study 
because the patients’ CD8 values were not measured at this center. There were CD3 
values available for a handful of patients, and this was not used in the analysis because 
it was not recorded for all the patients (Wilson et al 2002:47). Due to its wide variability, 
the baseline CD4 values were grouped into quadrants:  
• 1 (CD4 <50cells/mm3) 
• 2 (CD4= 50-<100 cells/mm3) 
• 3 (CD4=100-<200 cells/mm3), and  
• 4 (CD4= 200-<300 cells/mm3).  
 
A fifth group: 5 (CD4 >300 cells/mm3 ) was included because some patients might have 
attained high and normalised CD4 counts and maintained these counts without showing 
any increased CD4 counts during the time that this study was conducted. 
All the independent variables, identified during the literature review and included in the 
checklist, could not be addressed from the data available in the HIV clinic’s files. The 
independent variables considered for their influence on CD4 change percent in the 
current research were gender, age, HAART regimen, prior ARVs used, change of all 
NRTI or not, prior non-adherence to PIs, failing on the previous regimen just before 
switching to the current PI-based regimen, period without ARVs before starting on 
current PI-based regimen, type of regimens previously failed, previous switches 
between PIs, and baseline CD4 quadrant. Weights and staging of HIV disease were not 
analysed because these aspects were not recorded for every patient at each clinic visit. 
 
HIV-positive patients not on HAART record CD4 drops over time, while their VL rises. It 
was expected that the opposite would be the case in the research population on 
second-line HAART regimens as long as they were adherent to their medications. 
Having a trend of increasing CD4 and reduced VL counts in the patients could indicate 
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that they were adherent to HAART. Possible confounding variables that might impact on 
patients’ VL and CD4 counts were identified during the literature review, such as TB, 
cancer, major surgery, splenectomy, recent immunisations and pregnancy. Any of these 
variables in a patient’s files were recorded on the patient’s checklist (Avert 2011; 
MOHTT 2009:9).  
 
Falsely elevated CD4 counts, as seen in HTLV-1, could not be controlled because the 
HTLV-1 serology of the patients were analysed at the participating healthcare facility but 
it was not exactly clear at what point in their care that investigation was done. Some 
patients were given appointments to get the tests done but they did not go for the tests 
on the appointed dates. Splenectomies, which could increase patients’ CD4 counts 
falsely, were not recorded on any patient’s file. 
 
Medication adherence was assumed to be good for all the patients included in this 
research, based on the dates of their clinic attendances. Patients, who missed their 
clinic dates for refills of ARVs and who did not have ARVs to cover the period of non-
attendance at the clinic, were assumed to be non-adherent and were excluded from the 
study.  
 
There were occasionally recorded statements by the doctors of a few pills missed per 
month as verbalised by the patients, but this was not used to analyse adherence levels 
as the patients might not have provided accurate information and these records were 
infrequent. 
 
4.3    RESEARCH RESULTS 
 
Descriptive statistics were used for describing the respondents’ demographic 
characteristics and to measure associations using SPSS version 20. Several variables 
were tested and compared for their effect on the CD4 change percent. A significance 
level indicates how likely it is that a result is due to chance. The most common level, 
95% significance level means the finding concerned is 95% likely to be true.  
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Most statistical packages would show a 95% significance level as 0.05, also known as 
the p value meaning it has 5% chance of not being true. In this research, the p-value 
was set at <0.05 for statistical significance. Any p value in this research found to be 
greater than 0.05 implies that the result has a higher than 5% chance of not being true, 
and the finding was regarded as insignificant. Variables which were found to 
significantly affect CD4 change percent were tested for correlations to rule out 
confounders. 
 
Patients were started on their current PI-based regimens for reasons including failure on 
first line NNRTI-based regimens (68.5%; n=24), toxicity of NNRTI (14.2%; n=5 ), or prior 
PI-based regimens (n=3; 8.6%), to reduce pill burden of prior PI-based regimens (2.9%; 
n=3), pregnancy (5.7%; n=2), tuberculosis treatment (5.7%; n=2), transferred from other 
health care facilities already on PIs (5.7%; n=2) and in one patient’s file, the reason 
stated was “uncertainty”. Some of these patients were started on their current PI-based 
regimens for more than one of the recorded reasons.  
 
Out of the eight patients who had used other PI-based regimens before the current one 
two (25.0%) were switched for prior PI non availability; two (25.0%) for prior PI non 
adherence, one (12.5%) for having commenced TB treatment, three (37.5%) for side 
effects of prior PI-based regimens, and two (25.0%) at the patient’s request.  Some 
patients switched their regimens for more than one reason, explaining why the 
percentages do not add up to 100%.  
 
Variables which were tested for their influence on CD4 and VL include gender, age, 
HAART regimen, prior ARVs used, change of all NRTIs or not, prior non-adherence to 
PIs, failing on the previous regimen just before switching to the current PI-based 
regimen, period without ART before starting on current PI-based regimen, type of 
regimens previously failed, previous switches between PIs, and baseline CD4 quadrant. 
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4.3.1 The association of gender and baseline CD4 and CD4 change percent on PI-
based regimens 
 
 
Table 4.1: Baseline CD4 quadrant and gender (N=35) 
 
Of the 35 patients included in the analysis, there were 13 (37.1%) females and 22 
(62.9%) males.  In this study, the baseline CD4 was compared for both genders.   
The baseline CD4 quadrant was not significantly affected by gender (P=0.537) (see 
table 4.1). Therefore males and females did not have statistically significant different 
baseline CD4 counts in this study. 
 
Kumarasamy, Venkatesh, and Mayer (2008:1471) stated that there were higher CD4 
counts in ARV naïve HAART treated women in India compared to males, before and 
after one year on HAART.  These authors attributed this phenomenon to differences in 
physiological, immunological and clinical gender differences. However, in that study, 
NRTI-based regimens were used in ARV naïve patients. Thorsteinsson, Ladelund, 
Jensen-Fangel, Johansen, Katzenstein, Pedersen, Storgaard, Obel and Lebech 
(2012:293) demonstrated a higher baseline CD4 and lower baseline VL in women than 
in men before starting HAART, but immunological and virological responses were not 
significantly different for the two genders. In that study, both NNRTI-based and PI-
based regimens were used.  
 
Base CD4 
quadrant 
n Gender SD df p 
1: 1<50 4 1.25 .500   
2: 50<100 3 1.67 .577   
3:100<200 9 1.22 .441   
4: 200<300 5 1.60 .548   
55>300 14 1.36 .497   
Total 35 1.37 .490 34 .537 
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It was also revealed in a study in Senegal on HIV negative persons that men maintained 
a lower CD4 count than women (p<0.01) (Mair, Hawes, Agne, Sow, N’doye, Manhart, 
Gottlieb & Kiviat 2008:432-440). The findings of these studies appear to contradict the 
findings of the current research. However, the patients in the current research were not 
ARV naïve and the baseline CD4 was the CD4 taken just before the current PI-based 
regimen started, not before they commenced taking ARVs for the very first time in their 
lives. Some of the current study’s 35 respondents were on failing regimens (60.0%; 
n=21) while others were on successful regimens (40.0%; n=14) before commencing 
with their current PI-based regimens.   
 
Table 4.2:  CD4 change percent and gender (N=35) 
GENDER n Mean  SD df p 
1 (males) 22 67.14 108.035   
2 (females) 13 53.31 86.848   
Total 35 62.00 99.584 34 .698 
 
Response to therapy was also analysed for the patients on PI-based regimens (N=35) 
by comparing CD4 change percent for males (62.8%; n=22) and females (37.1%; 
n=13), and there was no statistically significant difference (p>0.698) (see table 4.2). 
Therefore in this research, the immunological responses to the PI-based regimens were 
not affected by gender.  There are conflicting literature reports on the effect of gender 
on CD4 increased counts while on HAART. Kumarasamy et al (2008:1) stated that there 
was higher CD4 after one year on HAART in females than males. A study comparing 
treatment outcomes of NNRTI-based regimens showed that being female was 
associated with greater CD4 increase on HAART (Gandhi, Spritzler, Chan, Asmuth, 
Rodriguez, Merigan, Hirsch, Shafer, Robbins & Pollard 2006:426-34). A study in 
Uganda (Sempa, Kiragga, Castelnuovo, Kamya & Manabe 2013:e73190) revealed that 
women who sustained virological suppression achieved a better sustained immunologic 
recovery than men. These studies’ findings seem to contradict the findings of the 
current study. However, the findings of a study by Smith, Sabin, Youle, Kinloch-de Loes, 
Lampe, Madge, Cropley, Johnson and Philips (2004:1860-1868), attempting to identify 
the factors influencing increases in CD4 cell counts in HIV patients on HAART, were 
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similar to the current study’s findings in that the CD4 cell increase on HAART was not 
affected by gender. Thorsteinsson et al (2012:293) also demonstrated that 
immunological and virological responses were not significantly different for the two 
genders  
 
4.3.2    Age and CD4 counts 
 
The 35 patients included in the analysis were categorised into the following age groups:  
• 1: 21-25yrs (n=0) 
• 2: 26-30yrs (n=2; 5.7%),  
• 3: 31-35yrs (n=5; 14.3%) 
• 4: 36-40yrs (n=7; 20.0%) 
• 5: 41-45yrs (n=5; 14.3%) 
• 6: 46-50yrs (n=7; 20.0%) 
• 7: 51-55yrs (n=4; 11.4%) 
• 8: 56-60yrs (n=3; 8.6%) and  
• 9: >61yrs (n=2; 5.7%).   
The basal CD4 quadrant was not significantly affected by age (p=0.296) (see table 4.3). 
Table 4.3:  Baseline CD4 quadrant and age groups (N=35) 
Baseline CD4 
quadrant 
                n Mean age 
group 
        SD df p 
1 (1<50) 4 5.50 1.291   
2 (50<100) 3 4.33 2.517   
3 (100<200) 9 6.00 2.000   
4 (200<300) 5 5.00 2.739   
5 (>300) 14 5.00 1.664   
Total 35 5.26 1.915 34 .296 
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In table 4.3 the usual age groups used throughout this chapter apply (group 1: 21-25 
years; group 2: 26-30 years; 3: 31-35 years; 4: 36-40 years; 5: 41-45 years; 6: 46-50 
years; 7: 51-55 years; 8: 56-60 years; 9: 61 years and older).  The means of the 
respondents’ age groups in each baseline CD4 quadrant were calculated.  The means 
of the respondents’ age groups ranged from 4.33 up to 6. As the age groups in all the 
baseline CD4 quadrants tended towards a mean of 5, no significant differences in the 
means of the respondents’ age groups were detected according to the baseline CD4 
quadrants.  Consequently, patients from similar age groups fell into all baseline CD4 
quadrants, implying that no significant correlation existed between age and baseline 
CD4 count. 
Table 4.4:  CD4 change percent and age group 
Age group           n Mean CD4 
change % 
SD df p 
2 (26-30yrs) 2 55.50 103.945   
3 (31-35yrs) 5 30.40 18.902   
4 (36-40yrs) 7 59.43 88.045   
5 (36-40yrs) 5 30.40 54.944   
6 (46-50yrs) 7 99.86 85.591   
7 (51-55yrs) 4 141.25 234.658   
8 (56-60yrs) 3 5.33 2.082   
9 (>61yrs) 2 29.50 13.435   
Total 35 62.00 99.584 34 .606 
 
There was no significant difference in the CD4 change percent, as shown in table 4.4, 
by age group (p=0.606). In this study the baseline CD4 and CD4 increase, while on PI-
based regimens, were not affected by age,   
 
Several studies done on the effects of age on CD4 recovery while on HAART have 
revealed conflicting results. It was concluded in a study on ARV--naïve persons, 
randomly assigned to start NNRTI-based regimens, that younger age was related to 
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higher CD4 cell increase (Gandhi et al 2006:426-34). The Eurosida study on both 
NNRTI-based and PI-based regimens revealed a higher CD4 response and required a 
shorter time to achieve maximal CD4 levels in the respondents falling within the 
younger age quartiles than those falling into older age groups (Viard, Mocroft, Chiesi, 
Kirk, Roge, Panos, Vetter, Bruun, Johnson & Lundgren 2001:1290-1294). However, a 
study on long term virologically suppressed adults in Australia suggests that increasing 
age does not result in decreasing mean changes in CD4 cell counts (Wright, 
Petoumenos, Boyd, Carr, Downing, O’Connor, Grotowski & Law 2013:208-16). The 
John Hopkins University AIDS service, also found (Greenbaum, Wilson & Gebo 2008:2) 
no difference in immune response between age groups, which is similar to the finding of 
the current research. Smith et al (2004:1860-1868) also revealed in their study that CD4 
cell increases among patients on HAART were not affected by age. 
 
4.3.3   CD4 count change by HAART regimen 
 
In figure 4.1, CD4 change percentage of patients on four different HAART regimens (1, 
2, 3 and 10) are displayed. There was a difference between regimens by CD4 change 
percent (p=0.000) (see figure 4.1 and table 4.5), in decreasing order from regimens 10 
(90%, SD 14.1), 2 (57.7%, SD 75.7), 3 (32.0%, SD41.7), and 1 (-9%, SD 4.4). 
(Regimens 4, 6, 7 and 12 were excluded from the analysis by the SPSS version 20 
software due to insufficient data).  
 
The significance in CD4 change percent between the PI-based regimens, analysed 
during the current study, might have been due to under representation of some 
regimens which were included in the analysis.  The number of respondents per regimen 
was too small to calculate any statistical significance 
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Fig 4.1 Regimen versus CD4 change percent (p=0.000) (n=27) 
 
 
Table 4.5: CD4 change percent by regimen for regimens: 1, 2, 3, 4, 6, 7, 10, 12 
(N=35) 
REGIMEN n Mean CD4 
Change % 
SD df P 
1 (AZT/3TC/ LPV/r) 2 -9.00 4.243   
2 (TDF/FTC/LPV/r) 23 57.70 75.789   
3 (TDF/FTC/ATZ/r) 4 32.00 41.785   
4 (TDF/FTC/DRV/r) 1 491.00 .   
6 (AZT/3TC/SQV/r) 1 13.00 .   
7 (ABC/3TC/LPV/r) 1 39.00 .   
10 (TDF/FTC/AZTLPV/r) 2 90.00 14.142   
12 (ABC/3TC/ATZ/r) 1 10.00 .   
Total 35 62.00 99.584 34 .000 
 
Although 15 PI-based regimens were used at the center participating in this study, only 
patients on 8 different regimens were qualified to be included in the study, namely 
regimens 1,2,3,4,6,7,10 and 12 (as shown in table 4.5).  
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Nevertheless, regimen 10, including TDF/FTC/AZT/LPV/r, seemed to be the best 
regimen when compared to the others, especially with regimen 2, which included 
TDF/FTC/LPV/r. The strategy of adding AZT in regimen 2 to create regimen 10, known 
as the super second line regimen, was created based on the belief that the M184V 
mutation, that developed in response to treatment with FTC and 3TC, causes a viral 
replicative defect and improved sensitisation of the virus to AZT, d4T and TDF (Gallant 
2007:453-455). However, a study in India showed no significant difference between 
these two regimens (Guha et al 2011). No difference in virological or immunological 
benefit was reportedly achieved by continuing 3TC in patients on HAART who 
harboured M184V mutations (Fox, Dragsted, Gerstoft, Phillips, Kjaer, Mathiesen, Youle, 
Katlama, Hill, Bruun, Clumeck, Dellamonica & Lundgren  2006).  
 
There were two patients on regimen 10 included in the analysis of the current study. 
One patient was a male on a NNRTI-based regimen, interchanging between EFV and 
NVP for five years.  Subsequently he had started on the supersecond line regimen 10. 
The reason for this choice of second line regimen was not clearly documented. The 
second patient on regimen 10, started on this regimen having previously failed  an 
NNRTI-based regimen and was on a PI-based regimen  in which there was only one 
NRTI change, and the doctor decided to place the patient on this super second line 
regimen 10. The superiority of regimen 10 (CD4 change of 90.0%, SD 14.1), 2 (CD4 
change of 57.7%, SD75.7), is a significant finding (p=0.000) which should be further 
investigated if similar outcomes are observed among large numbers of patients. 
 
Regimen 2 (CD4 change of 57.7%, SD75.7) was also superior to regimen 3 (CD4 
change of 32.0%, SD41.7), and 1 (CD4 change of -9%, SD 4.4) in decreasing order of 
superiority. Regimen 3 has a once daily regimen compared to regimens 1, 2 and 10 that 
require more frequent dosages.  Patients were usually placed on regimen 3 if there 
were fears of non-adherence due to pill burden. There were four patients on regimen 3 
included in this study. All of them had prior histories of not taking their first line regimens 
properly. One patient had a recorded resistance testing result showing resistance to 
ABC, 3TC, FTC and NNRTIs. She was susceptible to TDF, AZT and PIs. She was thus 
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placed on TDF/AZT/ATZ/r but was not taking the regimen properly due to vomiting, a 
side effect of AZT, and the regimen was stopped and switched to TDF/FTC/ATZ/r. 
Amongst individuals with documented M184V mutations (developed in response to 
treatment with 3TC or FTC), with or without additional NNRTI resistance, standard three 
drug boosted protease inhibitor-based regimens, containing 3TC “appeared equally 
effective at achieving virological suppression compared with more intensive multi-drug 
combinations or 3TC-sparing regimens” (Highleyman 2009). In the current study it could 
not be ascertained if the presence of M184V in the patient concerned affected the PI-
based regimen efficacy, as there was no resistance test result available for patients on 
the PI-based regimens. Fewer daily doses of ARVs are recommended for patients with 
adherence problems and patients are usually placed on this once daily regimen when 
they have adherence problems. The finding of lower efficacy in the once daily regimen 
might imply a lower adherence level to the once daily regimen by patients already 
known to have adherence problems. 
 
Of the two WHO (2010:55) recommended second line regimens 1 and 2, regimen 2 
(CD4 change of 57.7%, SD75.7) was apparently superior to regimen 1 (CD4 change of -
9%, SD 4.4) according to the findings of this study (p=0.000). Regimen 1 has fewer 
daily doses (3 pills twice daily) than regimen 2 (2 pills twice daily and third pill once 
daily). It is uncertain if this was the reason for the significant difference in efficacy or if it 
was due to under representation of the number of patients on regimen 1. 
 
A study in France compared once daily ATZ/r versus twice daily LPV/r, in combination 
with Tenofovir, the  same as the regimens 3 and 2 respectively in the current research, 
and found no difference in efficacy of the regimens (Molina, Andrade-Villanueva, 
Echevarria, Chetchotisakd, Corral, David, Moyle, Mancini, Percival, Yang, Thirty & 
McGrath 2008:646-655) after 48 weeks of monitoring. The same group of patients 
(N=883) were followed till 96 weeks on the same regimens and there was still no 
difference in efficacy between the two regimens (Molina et al 2010:323-32). These 
studies were done on ART-naïve patients. Johnson, Grinsztejn, Rodriguez, Coco, De 
Jesus, Lazzarin, Lichtenstein, Wirtz, Rightmire, Odeshoo  and McLaren (2006:711-8) 
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reported that in treatment experienced patients placed on ATZ/r versus twice daily 
LPV/r  in combination with TDF and another NRTI, there was no difference in efficacy, 
and ATZ/r demonstrated fewer side effects than LPV/r. The finding of a significant 
difference in efficacy of these two regimens (p=0.000) in the current study differs from 
all these studies’ reported findings.  However, it should be emphasised that the current 
study focused on a small number of patients on different regimens, and this could have 
influenced the statistics. 
 
In a study comparing once daily DRV/r with LPV/r in ART naïve patients bothin 
combination with TDF and FTC as in regimens 4 and 2 respectively revealed no 
inferiority of DRV/r compared to LPV/r (Ortiz, Dejesus, Khanlou, Voronin, Van Lunzen , 
Andrade-Villanueva, Fourie, De Meyer, De Pauw, Lefebvre, Vangeneugden & Spinosa-
Guzman 2008). The study also revealed a more favourable safety profile of regimen 4. 
The same study was carried out by Mills, Nelson, Jayaweera, Ruxrungtham, Cassetti, 
Girard, Workman, Dierynck, Sekar, Abeele and Lavreys (2009:1979-88) and revealed 
once-daily DRV/r was superior in virologic response to LPV/r, with a more favourable 
gastrointestinal and lipid profile, confirming DRV/r as an effective, well tolerated, and 
durable option for ARV-naive patients. In the current study, regimen 4 was not included 
in the analysis by the SPSS software due to insufficient sample size, so its efficacy 
could not be compared to that of regimen 2.  
 
Ferradini et al (2011:14) demonstrated a high rate of virological supression and immune 
reconstition after 24 months on LPV/r-based second line regimens in Cambodia. 
However, no comparisons were made between the four regimens included in that study: 
ddI/3TC/LPV/r (65.7%), ddI/TDF/LPV/r (10.0%), ddI/AZT/LPV/r (8.6%) and TDF/3TC/LPV/r 
(7.1%). In the current study,  at six months, the mean CD4 increase was 65 cells/mm3, 
SD 100 and this was deemed to be an acceptable level. This means the efficacy of the 
PI-based regimens in use at the SFGH were at an acceptable level based on CD4 
increase percent as at the end of 2013. However, regimen 10 was superior to the other 
7 regimens used to treat the patients at the participating clinic, as analysed during the 
current study (see table 4.5). 
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4.3.4    Prior HAART history 
 
The 35 patients on PI-based regimens were categorised into three groups: 
• 1: patients who previously used NNRTI-based regimens only (40.0%; n=14) 
• 2: patients who had previously used both NNRTI-based and PI-based regimens 
(40.0%; n=14) 
• 3: patients who had used only PI-based regimens before starting on the current 
PI-based regimens (20.0%; n=7). 
 
Table 4.6: CD4 change percent correlated with previously used ARVs (N=35) 
 
Previously used ARVs n Mean CD4 
change % 
SD df p 
1  (NNRTI-based only) 14 96.64 132.563   
2 (NNRTI- and PI-based) 14 23.07 23.718   
3 (PI-based only) 7 70.57 102.372   
Total 35 62.00 99.584 34 .143 
 
 
When ARV experienced patients are started on second line drugs, they might have 
developed HIV mutation and resistance to the first line ARVs.  This could affect the 
efficacy of their current PI-based regimens. It was based on these assumptions that the 
patients were categorised into three groups. However, there was no statistically 
significant difference in CD4 change percent in these three groups of patients; 1 (CD4 
change of 96.6%, SD 132), 2 (CD4 change of 23.0%, SD23.7) and 3 (CD4 change of 
70.57%, SD 102.3), (p= 0.143) (see table 4.6). Having used NNRTI-based or PI-based 
regimens prior to being placed on the current PI-based regimens did not have an effect 
on the CD4 change percent in the group of patients included in this study (N=35). 
 
The most common mutation to NNRTIs is the K103N which occurs in 30%-50% of 
patients while on failing regimens with NVP and EFV (Mackie 2006). Delobel, Saliou, 
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Nicot, Dubois, Trancart, Tangre, Aboulker, Taburet, Molina, Massip, Marchou and 
Izopet (2011) investigated the impact of K103N mutation on subsequent virological 
response to combination ART. These authors found that one patient who had confirmed 
N103R mutation had a virological response to treatment with a combination of IDV (a 
PI), EFV and 3TC despite a high level frequency of the K103N, and this response was 
attributed to the PI-bsed regimen. However, that study was inconclusive. In the current 
study, only one patient had a resistance test confirming the presence of the N103R 
mutation which confers resistance to NNRTIs. Even though she was placed on once 
daily PI-based regimen 3, the efficacy of this regimen was less than that of regimens 10 
and 2 which had higher pill loads. It is uncertain if the confirmed K103N mutation had an 
impact on the regimen’s efficacy, or if the patient was non adherent to the PI-based 
regimen, having had prior episodes of non-adherence to NNRTI-based and also to the 
same PI-based regimens.  
 
Buchacz, Baker, Ward, Palella, Chmiel, Young, Yangco, Novak and Brooks 
(2012:230290) reported a decrease in the PI resistance in PI experienced patients from 
71% to 46% since the increased use of RTV-boosted PIs from 5% to 81% during the 
period 1999-2008. Several studies have been collated on the response to new PI-
containing regimens in patients with PI-resistance mutations (PI-resistance mutations. 
Phenotypic susceptibility scores predict HIV response in PI-experienced patients 
(Swanstrom, Bosch, katzenstein, Cheng, Liang, Hellmann,  Haubrich, Fiscus, Fletcher, 
Acosta & Gulick 2004:886-893). Documented mutations at protease positions 10, 20, 
24, 33, 36, 47, 48, 54, 82 and 84 were associated with virological resistance to LPV/r 
(Grant, Wong, Rode, Shafer, De Luca, Nadler, Hawkins, Cohen, Harrington, Kempf & 
Zolopa 2008:4050-6; King, Rode, Cohen-Codar, Calvez, Marcelin, Hanna & Kempf 
2007:3067-74 ).  In the current study, baseline resistance results were not taken into 
consideration because it was not done for all the patients included in the study. If prior 
use of NNRTI or PI had significantly affected the CD4 change percent, they might have 
developed resistance to the previously used regimens 
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The effect of prior regimens used by the patients included in this study, on their 
immunologic recovery might be related to the history of changing all NRTIs or not to do 
so, regimens previously confirmed failed, prior non-adherence to PIs and previously 
switching between PI regimens, which will be discussed in later sections of this report. 
 
4.3.5     CD4 change percent and changing all NRTIs 
 
It is recommended by the WHO (2010:53-57) that the NRTI backbone used in first line 
regimens, should be changed when starting a new  second line regimen, as mutations 
might have developed in response to the first line NRTIs. In order to test whether or not 
this affected the efficacy of the regimens, the 35 patients on the current PI-based 
regimens were categorised into two groups: 
• 1: all NRTIs changed (f=26; 74.3%) 
• 2: all NRTIs not changed (f=9; 25.7%) 
 
Table 4.7: CD4 change percent and changing of all NRTIs (N=35) 
 
All NRTIs 
changed 
n Mean CD4 
change % 
SD df p 
1 (yes) 26 55.08 96.753   
2 (no) 9 82.00 110.849   
Total 35 62.00 99.584 34 .493 
 
There was no statistically significant difference in CD4 change percent between the two 
groups; 1 (CD4 change of 55.0%, SD 96.8) and 2 (CD4 change of 82.0%, SD 110.8), 
(p=0.493) (see table 4.7). In this study, after using first line medications, changing all the 
NRTI backbone or not doing so had no effect the CD4 change percent when the 35 
patients commenced PI-based second line regimens.  
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The finding of no significance was in keeping with other research findings. Medecins 
Sans Frontieres documented favourable outcomes observed in PI-based second-line 
regimens with at least one NRTI change. Hull et al also demonstrated that  amongst 
individuals with documented M184V mutations (developed in response to treatment with 
3TC or FTC), with or without additional NNRTI resistance, standard three drug  boosted 
protease inhibitor–based regimens containing 3TC, “appeared equally effective’’ at 
achieving virological suppression compared with more intensive multi-drug 
combinations or 3TC-sparing regimens. These statements are similar to the findings in 
the current research. This means starting second line PI-based regimens is feasible in 
resource-limited settings with a limited number of available NRTIs, with outcomes which 
may be similar to that in resource-rich countries where several alternative NRTIs are 
available (Highleyman 2009; Pujades-Rodríguez et al 2008:1305-1312). 
 
4.3.6     Prior non adherence to PIs 
 
Confirmed failure to any regimen involves confirmed adherence to that regimen, with 
virological, immunological and sometimes clinical failure on treatment with that specific 
regimen. Resistance studies could also confirm the presence of resistance mutations. 
Non adherence might lead to the development of drug resistance. 
 
Table 4.8: CD4 change percent and prior non adherence to PIs (N=35) 
 
Prior non-adherence to 
PI 
n Mean CD4 
change % 
SD df p 
1 (yes) 10 46.20 87.049   
2 (no) 25 68.32 105.175   
Total 35 62.00 99.584 34 .561 
 
Patients were started on their current PI-based regimens for reasons including failure on 
first line NNRTI-based regimens (68.5%; n=24), toxicity of NNRTI (14.2%; n=5 ), or prior 
PI-based regimens (n=3; 8.6%), to reduce pill burden of prior PI-based regimens (2.9%; 
n=3), pregnancy (5.7%; n=2), tuberculosis treatment (5.7%; n=2), transferred from other 
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health care facilities already on PIs (5.7%; n=2) and in one patient’s file, the reason 
stated was “uncertainty”. Some of these patients were started on their current PI-based 
regimens for more than one of the recorded reasons. No patient had documented 
confirmation of failure to PI-based regimens before starting his/her current PI-based 
regimens. However, in some patients who were non-adherent to previous PI-based 
regimens, it was assumed that there was the possibility of some resistance mutations to 
PI-based medications. It was based on this that the 35 patients on current PI-based 
regimens were categorised into two groups:   
• 1: prior non adherence to a PI-based regimen (28.6%. n=10) 
• 2: no prior non adherence to a PI-based regimen (71.4%; n=25) 
 
There was no statistically significant difference in CD4 change percent between the two 
groups; 1 (CD4 change of 46.2%, SD 87.0) and 2 (CD4 change of 68.3%, SD 105.1) 
(p= 0.561) (see table 4.8). Thus having a history of non-adherence to previous PI-based 
regimens did not affect the CD4 change percent in the current PI-based regimens. PIs 
are known to have high genetic barriers to developing resistant mutations, and this may 
be the reason for the non-significance of prior PI non-adherence. However, resistance 
tests were not done for all the patients before starting on the current PI-based regimens 
so an assessment of the effect of any mutations which confer resistance to PIs was 
impossible (Demeter et al 2008; WHO 2010: 55-56). 
 
4.3.7:  CD4 change percent correlated with being on a failing regimen just before 
switching to the current PI-based regimen 
 
All the patients were HAART experienced. Some were on successful HAART 
medications, but were switched to their current PI-based regimens for reasons including 
failure on first line NNRTI-based regimens (n=24;7% ), toxicity of NNRTI (5;1% ), or 
prior PI-based regimens (3; 9%), to reduce pill burden of prior PI-based regimens(1; 
3%), pregnancy (2; 6%), tuberculosis treatment (2; 6%), transferred in already on PIs (2; 
6%) and in 1(3%)  patient, the reason started on the current PI-based regimen was 
uncertain. 
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Figure 4.2: CD4 change percent and being on a failing regimen before current PI 
(N=35) 
 
Some patients started their current PI-based regimens for more than one of the 
recorded reasons. The 35 patients on current PI-based regimens were categorised into 
two groups based on whether or not they were on failing regimens just before their 
current PI regimens: 
● 1: they were on failing regimens just before their current PI-based regimens (60.0%; 
n=21) 
● 2: they were not on failing regimens just before their current PI-based regimens 
(40.0%; n=14) 
 
Table 4.9: CD4 change percent and use of a failing regimen just before current PI 
regimen (N=35)  
On failing regimen 
just before current PI 
n Mean CD4 
change % 
SD Df p 
1 (yes) 21 91.4 119.129   
2 (no) 14 17.9 24.610   
Total 35 62.0 99.584 34 .030 
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This categorisation was based on records written by the doctors on the patients’ files. 
There were 21 (60.0%) patients in group 1 and 14 (40.0%) patients in group 2. There 
was a statistically significant difference in CD4 change percent in the two groups; 1 
(CD4 change of 91.4%, SD 119.1) and 2 (CD4 change of 17.9%, SD 24.6) (p= 0.03) 
(see figure 4.2 and table 4.9), indicating that patients who were on failing regimens 
before their current PI-based regimens had a higher CD4 change percent than those 
who were on successful regimens. Of note is that patients on failing regimens were 
expected to have lower baseline CD4 counts before commencing their current PI-based 
regimens. The next section (4.3.8) attempts to make a connection between the two 
variables: on failing regimen before current PI-based regimens and baseline CD4. The 
baseline CD4 has also been related to CD4 change percent in several studies and this 
will be addressed in section 4.3.8.  
 
4.3.8 Baseline CD4 and failing regimen just before current PI 
 
When the CD4 baseline quadrants were compared on the variable whether the patients 
were on failing regimens just before starting current PI-based regimens, there was a 
statistically significant difference between the two groups (p=0.021) (see figure 4.4 and 
table 4.10). The patients who were on successful regimens (group 2), had the higher 
baseline CD4 quadrant. This difference was expected, as patients on failing regimens 
were expected to have lower CD4 values. 
 
The correlation between having a lower CD4 baseline quadrant and being on a failing 
regimen just before current PI-based regimens was also expected to be reflected in the 
CD4 change percent compared to baseline CD4 quadrants. This is the case as patients 
on a failing regimen before their current PI-based regimens, have been shown to have 
significantly higher CD4 change percent than patients not on failing regimens (p=0.030) 
as discussed in section 4.3.7. This is addressed in the next section. 
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Fig 4.3 Baseline CD4 quadrant and being on failing regimen just before current PI-
based regimen p=0.021. On failing regimen just before current PI: 1(yes) and     
2(no). Baseline CD4 Quadrants: 1<50, 2=50-100, 3=100-200, 4=200-300 and 5>300 
cells/mm3 
 
 
Table 4.10: Baseline CD4 and failing regimen just before commencing with the 
current PI (P=0.02). On failing regimen just before current PI: 1(yes) and 2(no). 
Baseline CD4 Quadrants: 1<50, 2=50-100, 3=100-200, 4=200-300 and 5>300 
cells/mm3 
On failing regimen 
just before current PI 
n Mean SD Df p 
1 (yes) 21 3.10 1.480   
2 (no) 14 4.43 .756   
Total 35 3.63 1.395 34 .021 
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4.3.9    Baseline CD4 quadrant and CD4 change percent 
 
The 35 patients on current PI-based regimens were grouped according to their baseline 
CD4 by categorising them into five groups, as shown in table 4.1. There was a 
statistically significant difference in CD4 change percent in these groups; 1 (CD4 
change of 237.5%, SD 180.3), 2 (CD4 change of 97.0%, SD 33.6), 3 (CD4 change of 
62.44%, SD 87.3), 4 (CD4 change of 18.8%, SD 44.8) and 5 (CD4 change of 19.5%, 
SD 22.7) (p=0.000) (see fig 4.4 and table 4.11). The CD4 change percent was highest 
in the lowest baseline CD4 quadrant, and was in decreasing order from 1, 2, 3, 4 and 5. 
This means patients starting their PI-based regimens at lower CD4 levels achieved a 
higher CD4 change percent than patients with higher baseline CD4. After examining the 
results of section 4.3.7 (CD4 change percent was higher in patients failing regimen just 
before switching to current PI-based regimen (p=0.03)) and 4.3.8 (baseline CD4 was 
lower in patients failing regimen just before current PI (p=0.021)), this correlation was 
expected in this section. 
 
 
Fig 4.4 CD4 change percent and baseline CD4 quadrants (p= 0.000) (N=35) 
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Table 4.11: Baseline CD4 quadrant and CD4 change percent (N=35) 
Baseline CD4 
quadrant 
n Mean SD Df p 
1 4 237.50 180.352   
2 3 97.00 33.601   
3 9 62.44 87.396   
4 5 18.80 44.824   
5 14 19.50 22.698   
Total 35 62.00 99.584 34 .000 
 
 
Literature reveals conflicting reports about the effect of baseline CD4 on immune 
recovery. Smith et al (2004:1860-1868) revealed that CD4 cell increases on HAART 
were higher in patients with lower baseline CD4 counts. Lawn, Myer, Bekker and Wood 
(2006:6-59) also reported a higher CD4 cell recovery on ART in patients with lower CD4 
counts at baseline. These were similar to the findings of this study where the patients at 
lower baseline CD4 counts achieved significantly (p=0.000) higher CD4 change percent 
than those who started at higher baseline CD4 cell counts. However, a study comparing 
CD4 increase on NNRTI-based regimens revealed higher CD4 cell increase in patients 
with higher baseline CD4 counts (Gandhi et al 2006:426). 
 
It is possible that the results of the current study were arrived at because some patients 
were on successful regimens before starting their current PI-based regimens, and had 
normal CD4 levels.  Due to the normal variation in CD4 counts, the CD4 level might 
have swayed up or down in patients whose CD4 levels had been normalised. There 
were no CD8 values recorded for these patients to confirm who had a normal variation 
or an actual decreased CD4 count.  
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4.3.10 CD4 change percent and period without ARVs 
 
Table 4.12: CD4 change percent and no-ARVs period before current PI regimen 
(N=35) 
 
No ART period 
before starting PI 
n Mean SD df p 
1 (yes) 5 78.40 119.812   
2 (no) 30 59.27 97.942   
Total 35 62.00 99.584 34 .697 
 
 
Table 4.13: Baseline CD4 quadrant and period off ART before 
current PI-based regimens (ANOVIA). Baseline CD4 Quadrants: 
1<50, 2=50-100, 3=100-200, 4=200-300 and 5>300 cells/mm3 
 
 Sum of 
Squares 
df Mean Square F Sig. 
Between Groups .005 1 .005 .002 .961 
Within Groups 66.167 33 2.005   
Total 66.171 34    
 
 
Some patients who had to be started on their current PI-based regimens were off ARVs 
for a period before commencement of their current regimens. The 35 patients on current 
PI-based regimens were categorised into two groups based on whether there was a 
period of no ART before starting current PI-based regimens. Five (14.3%) patients 
discontinued taking ARVs while 30 (85.7%) patients had no such ART discontinuation. 
Two patients defaulted on their PI-based regimens for no obvious reason; one patient 
had stopped taking her ARVs because she used it for PMTCT which was stopped after 
delivery (period off ART=22 months) and another patient was on PI-based regimen for 
resistance to NNRTI but defaulted on his own (period off ART=36 months). One patient 
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was placed on a PI-based regimen because he had TB, but he was non-compliant and 
the doctor stopped him (period off ART=5 months). The other two patients stopped 
because they experienced side effects caused by LPV/r and were later restarted on the 
same regimens (period off ART=24 and 2 weeks respectively). 
 
It is assumed that a period on no ART might contribute to a drop in baseline CD4 and 
thus to the CD4 change percent when restarted on HAART. There was no statistically 
significant difference in CD4 change percent in these two groups (p=0.697) (see table 
4.12). Having a no-ART period before restarting the current PI-based regimens did not 
affect the CD4 change percent of the patients on these PI-based regimens.  
 
The two groups were then compared based on their baseline CD4 quadrants. There 
was no statistically significant difference in the CD4 baseline quadrants of the two 
groups (p= 0.961) (see table 4.13). It would have been expected that patients who were 
off ARVs for a period of time would have a lower basal CD4 quadrant, but this was not 
the finding in this research. These patients were probably not on successful regimens 
before their previous ARVs were stopped, so they might have been comparable in their 
basal CD4 quadrant to patients on ineffective HAART who might also have been 
classified as being on failing regimens just before their current PI-based regimens were 
commenced. Or maybe these patient did not have an absolute need for ART for 
immune reconstitution at the time they were started on it. Of the five patients who were 
off ART, only one (patient 22) had confirmed failure and resistance to first line NNRTI 
regimen necessitating him to start on a PI-based regimen. 
 
4.3.11    CD4 change percent and previously failed regimens 
 
Confirmed failure on any regimen involves confirming virological and immunological 
failure on a regimen to which the patient is adherent. This information was obtained 
from the doctor’s documentation on the medical records of the patients 
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Table 4.14: CD4 change percent and prior regimens failed (N=35) 
 
Prior regimens failed n Mean CD4 
change % 
SD df P 
0 (never any prior 
failure) 
9 22.11 27.200 
  
1 (prior failure) 26 75.81 111.710   
Total 35 62.00 99.584 34 .167 
 
 
The 35 patients on current PI-based regimens were categorised into three groups, 
based on their failed regimens before their current PI-based regimens. 
• 0: never failed any regimens (25.7%; n=9) 
• 1: previously failed NNRTI-based regimens (74.3%; n=26) 
• 2:previously failed both NNRTI and PI based regimens (n=0) 
 
None of the patients had previously failed a PI regimen. Only two groups, 0 and 1 were 
compared. There was no statistically significant difference in CD4 change percent in the 
two groups; 1 (CD4 change of 22.1%, SD 27.2) and 2 (CD4 change of 75.8%, SD111.7) 
(P= 0.167). Baseline resistance testing was not done in this research. Patients who had 
failed the NNRTI-based regimens might have developed resistant mutations to NNRTIs. 
Since this did not affect the CD4 change percent on the current PI-based regimen, it 
could be assumed that resistant mutations to NNRTI did not affect the PI-based 
regimen efficacy. This is similar to the finding in the study by Delobel et al (2011) who 
investigated the impact of K103N mutation on subsequent virological response to 
combination ART. These authors found that one patient who had confirmed N103R 
mutation, had a virological response to treatment with a combination of IDV (a PI), EFV 
and 3TC despite a high level frequency of the K103N, and this response was attributed 
to the PI-based regimen.  
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Several studies have examined the effect of previously used regimens on PI efficacy. 
Documented mutations at protease positions 10, 20, 24, 33, 36, 47, 48, 54, 82 and 84 
were associated with virological resistance to LPV/r (Grant et al 2008:4050-6; King et al  
2007:3067-74). In the current research, baseline resistance results were not taken into 
consideration because it was not done for all the patients included in the study. No 
patient had a history of having failed on a PI-based regimen.  Thus there was no reason 
to suspect that the 35 patinets participating in the current study harboured PI resistant 
mutations. 
 
4.3.12 Previous switches between PI regimens  
 
Patients who had used other PI-based regimens before the current one (22.9%; n=8) 
were switched for prior PI non availability (25%; n=2), prior PI non-adherence (25%; 
n=2), commenced TB treatment (12.5%; n=1), side effects of prior PI-based regimens 
(37.5%; n=3) and at the patient’s request (25%; n=2). Some patients switched regimens 
for more than one reason. The 35 patients on current PI-based regimens were grouped 
into two groups based on whether they previously switched between PI-based regimens 
or not. 
 
Table 4.15: CD4 change percent and history of switching PIs. Switched PIs 
(N=35) 
Switched btw 
PIs 
N Mean CD4 
change % 
SD Df P 
1 (yes) 8 12.13 15.376   
2 (no) 27 76.78 109.144   
Total 35 62.00 99.584 34 .108 
 
 
There was no statistically significant difference in CD4 change percent in the two 
groups; 1 (CD4 change of 12.1%, SD 15.4) and 2 (CD4 change of 76.8%, SD109.1) (p= 
0.108). Prior use of PI-based regimens before commencing with the current PI-based 
regimens did not affect the CD4 change percent on the current PI-based regimens. This 
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relation was important because if the patient failed on a previous PI-based regimen, the 
patient might have developed resistant mutations to the previous PI-based regimen and 
the effect of that on the current PI-based regimen might have been noticed in the CD4 
change percent. None of the eight (22.9%) patients who switched PIs had done so for 
failure of a previous PI-based regimen. Even though two patients were switched PI-
based regimens for non-adherence to their regimens, this did not affect the efficacy of 
the subsequent PI-based regimen, possibly due to the PI’s high genetic barrier to 
resistance (Demeter et al 2008). Resistance tests were not routinely done before 
starting any new regimen so it could not be determined if any resistant mutations 
developed due to use of previous PI-based regimens. 
 
4.3.13  Regimens and baseline CD4 quadrant 
 
As it appeared the baseline CD4 count was significant in the CD4 change percent 
(p=0.000), an analysis was carried out to determine if there was a difference in baseline 
CD4 counts between regimens. There was no significant difference between the 
baseline CD4 count of the regimens (p=0.323) (see table 4.16), thus this possible 
confounder did not account for the difference in efficacy between the regimens. 
Table 4.16: Correlation of Baseline CD4 quadrant and regimen (N=35) 
 
REGIMEN n Mean SD df P 
1 (AZT/3TC/ LPV/r) 2 5.00 .000   
2 (TDF/FTC/LPV/r) 23 3.70 1.490   
3 (TDF/FTC/ATZ/r) 4 3.50 .577   
4 (TDF/FTC/DRV/r) 1 1.00 .   
6 (AZT/3TC/SQV/r) 1 5.00 .   
7 (ABC/3TC/LPV/r) 1 3.00 .   
10 (TDF/FTC/AZTLPV/r) 2 2.50 .707   
12 (ABC/3TC/ATZ/r) 1 4.00 .   
Total 35 3.63 1.395 34 .323 
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4.3.14  Viral load 
 
VL was recorded as undetected once it was less than 400/ml for the 35 patients 
included in this study. Undetectable viral load is required for immune recovery. All the 
patients who had VL results at six months had undetectable VL so this parameter was 
not used for comparing the outcomes of the different regimens.  However, it could be 
concluded that all 35 patients achieved an acceptable level of efficacy on their PI-based 
HAART regimens after six months on treatment by having undetectable VL counts. 
 
Table 4.17:  Viral blip and regimen 
 Sum of 
Squares 
df Mean Square F Sig. 
Between Groups .417 7 .060 .691 .679 
Within Groups 2.326 27 .086   
Total 2.743 34    
 
 
Viral blips are isolated elevations in VL that do not predict subsequent virological failure 
(CDC 2013).  Low levels (50-1000 copies/ml) have been found frequently and are short 
lasting, with no effect on clinical stage  while high level viraemia (>1000 copies/ml) was 
more frequently associated with resistance and therapy changes (Van Sighem, Zhang, 
Reiss, Gras, Van der Ende, Kroon, Prins & De Wolf  2008:104-8).  
 
Of the 35 patients included in the study, two patients had virological blips recorded in 
their files during treatment on their PI-based regimen one at 18 months (a female, 
VL=1503 copies/ml) and the other at 12 months (a male, VL=708copies/ml).The female 
was on regimen 1 and the male was on regimen 2. Both had recorded undetectable VL 
at six months on their PI-based regimens and the VL repeated after three months of the 
blip were undetectable for both patients. The female patient had a higher viral blip and 
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admitted to having had unprotected sex at the time when the viral blip was detected. 
There was no statistically significant incidence of viral blip by regimen (p=0.679). So 
none of the regimens were more likely than others to lead to regimen failure. 
 
4.3.15   The correlation of anaemia with PI-based regimens 
 
Haemoglobin levels of less than 10 mg/dl were taken as indicating anaemia. A total of 
30 patients included in this research had baseline and follow up haemoglobin levels 
recorded at 6, 12 and 18 months. Only one patient out of these 30 had developed 
anaemia after starting the PI-based regimen.  
Table 4.18:  The development of anaemia on different regimens (n=30) 
 
 
 Frequency Percent Valid Percent Cumulative 
Percent 
 
1(yes before starting regimen) 1 3.3 3.3 3.3 
2 (yes after starting regimen) 1 3.3 3.3 6.7 
3 (did not develop anaemia) 28 93.3 93.3 100.0 
Total 30 100.0 100.0  
 
These 30 patients (with haemoglobin records) were categorised into three groups based 
on whether they had anaemia or not: 
• 1: yes, before starting the PI-based regimen (3.3%; n=1) 
• 2: yes, after starting the PI-based regimen or (3.3%; n=1) 
• 3: did not develop anaemia (93.3%; n=28) 
 
4.3.16    Renal impairment on PI-based regimens 
 
Persistent Creatinine levels above 2.0mg/dl were regarded as renal impairment. No 
patient included in this study had renal impairment before or during treatment with their 
current PI-based regimens. 
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4.3.17   High lipids on PI based regimen 
 
Elevated lipids are a known side effect of the Protease inhibitor class. Cholesterol and 
triglyceride levels above 200mg/dl were regarded as being elevated. 
 
 
Table 4.19:  Increased cholesterol levels on PI-based regimens 
 
Developed high cholesterol levels Frequency Percent Valid Percent Cumulative Percent 
 
1 (yes before starting 
regimen) 
2 6.5 6.5 6.5 
2 (yes after starting 
regimen) 
2 6.5 6.5 12.9 
3 (did not develop high 
cholesterol) 
27 87.1 87.1 100.0 
Total 31 100.0 100.0  
 
Patients were categorised into three groups based on whether they had increased lipids 
while on their PI based regimens. 
● 1: increased lipids before starting the regimen 
● 2: increased lipids after starting regimen  
● 3: did not develop increased lipids.  
 
Table 4.20   Increased triglyceride levels on PI-based regimens 
 
 Frequency Percent Valid 
Percent 
Cumulative 
Percent 
 
1 (yes before starting PI-regimen) 2 6.7 6.7 6.7 
2 (yes after starting PI regimen) 5 16.7 16.7 23.3 
3 (no did not develop high 
triglycerides) 
23 76.7 76.7 100.0 
Total 30 100.0 100.0  
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4.4    OVERVIEW OF RESEARCH FINDINGS 
 
The total efficacy of all the PI-based regimens in use at the SFGH was at an acceptable 
level. It met the required standards of undetected VL by six months for all the patients, 
and the average CD4 cell increase was 65, SD 99.8 after six months on HAART. There 
was a significant difference in potency of the regimens (p=0.000).  
 
Regimen 10 was the most potent (p=0.000), but it is uncertain if this was a due to non- 
representation of the other regimens due to small numbers of patients in the different 
regimen groups. The most important variable which seemed to affect CD4 change 
percent was the baseline CD4 (p=0.000) which was also significantly related to whether 
or the patient was on a failing regimen before starting the current PI-based regimen (p= 
0.021). There was no statistically significant difference in the baseline CD4 counts of 
patients on the different regimens (p=0.323). Hence it was inferred that, even though 
lower baseline CD4 was associated with higher CD4 change percent (p=0.000), the 
difference in efficacy of the regimens (p=0.000) was not attributable to the patients’ 
baseline CD4 counts when they started on the PI-based regimens. 
 
In the current research, other factors such as age (p= 0.606), gender (p=0.698), prior 
use of ARVs (p= 0.143), change of all NRTIs or not (p=0.493), prior failed regimens (p= 
0.167), and prior non adherence to PIs (p=0.561) did not have any significant effect on 
CD4 change percent. 
 
4.5   SUMMARY    
 
A repeat study needs to be carried out to examine the specific potency of the regimens 
and the CD4 change percent and related variables as these results will have a great 
impact in the improvement of patient care. 
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CHAPTER 5 
 
CONCLUSIONS, RECOMMENDATIONS AND LIMITATIONS OF 
THE STUDY 
 
5.1    INTRODUCTION 
 
The purpose of the study was to compare patients’ treatment outcomes (CD4 cell count 
and VL six months after commencing treatment) of the PI-based (second line) HAART 
regimens in Trinidad.  It was impossible to evaluate the clinical outcomes (WHO stages) 
because these were not recorded on the patients’ files.  The impact of the following 
variables that could impact on these treatment outcomes were considered: patients’ 
treatment adherence levels, baseline as well as subsequent CD4 counts and VL levels, 
and OIs. 
 
5.2   CONCLUSIONS 
 
The conclusions will be presented according to the objectives stated in section 1.4.2 of 
this thesis.  Gender had no impact on baseline CD4 quadrant (P=0.537) and CD4 
change percent (p=0.698) on the treatment outcomes of the current PI-based regimens. 
Age also had no effect on baseline CD4 quadrant (p=0.296) and CD4 change percent 
(p=0.606) in patients on PI-based regimens in the current research.  
 
Several variables, identified in the literature review, could not be tested in the current 
study. Diurnal variations in CD4 levels were not applicable as all the tests were 
scheduled to be done during the morning hours at the HIV clinic of the SFGH on the 
patients’ scheduled testing dates. Laboratory variations were also not applicable as all 
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the tests were done by the same laboratory. Weight and staging were not compared for 
the patients on the PI-based regimens because these were not recorded for all the 
patients.  The known damaging effect of corticosteroid and interferon administration 
were not investigated as there were no records of patients using these drugs.  
 
5.2.1    Baseline CD4 and VL counts compared with these counts at 6, 12 and 18 
months of treatment on PI-based HAART regimens 
 
Due to the quality of records in the patients’ files, CD4 and VL counts could only be 
determined at baseline and at 6 months’ PI-based HAART. Consequently the initial 
objective of measuring these outcomes at 12 and 18 months after commencing PI-
based HAART regimens had to be abandoned. 
 
Patients with lower baseline CD4 had a higher CD4 change percent than those with 
higher baseline CD4 (P=0.000). The most important factors which seemed to affect CD4 
change percent were the regimen in use and the basal CD4 at which the PI-based 
regimens were started. The factor found to be directly related to the baseline CD4 was 
being on a failing regimen just before commencing the current PI-based regimen. 
Patients on failing regimens had lower baseline CD4 quadrants and a higher CD4 
change percent on their PI-based regimens than patients falling in the higher CD4 
quadrants. 
 
Factors found to have no effect on regimen efficacy included prior HAART history, 
changing all NNRTIs or not, prior non adherence to PIs, a period on no ART before the 
current PI-based regimen, previously failed regimens and previous switches between 
PI-based regimens 
 
5.2.2    HAART adherence levels as measured by regular clinic attendance 
 
Having a history of non-adherence to previous PI-based regimens did not affect the 
CD4 change percent in the current PI-based regimens. PIs are known to have high 
genetic barriers to developing resistant mutations, and this might be the reason for the 
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non-significance of prior PI-based HAART regimens and non-adherence. However, 
resistance tests were not done for all the patients, before starting on the current PI-
based regimens, so an assessment of the effect of any mutations which might cause 
resistance to PIs was impossible 
 
5.2.3   The World Health Organization developmental stage of AIDS 
 
This could not be determined as the WHO developmental stage of AIDS was not 
recorded in the patients’ files.  Consequently no relevant information could be used from 
these files to identify whether the patients’ WHO developmental stage of AIDS improved 
after being put on PI-based HAART regimens.  
 
5.2.4   Opportunistic infections 
 
No information was reported in the patients’ files about OIs.  Consequently this 
objective, of correlating the occurrence of OIs with PI-based HAART outcomes, could 
not be realised. 
 
5.2.5   Side effects of PI-based HAART regimens as reported by the patients 
 
The patients’ records were scrutinised for side effects of anaemia, renal impairment and 
increased lipids while on treatment with their current PI-based regimens. One patient 
(3.3%) had anaemia before commencing on the current PI-based regimen. One patient 
(3.3%) had anaemia after commencing on the current PI-based regimen. Twenty eight 
patients (93.3%) did not have any documentation of anaemia.  
 
There was no patient with recorded renal impairment on any of the regimens.  
 
Two patients (6.5%) had high cholesterol levels before commencing the current PI-
based regimen. Two patients (6.5%) had high cholesterol levels after commencing the 
current PI-based regimen. Twenty seven patients (87.1%) did not have any 
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documentation of high cholesterol. Two patients (6.7%) had high triglyceride levels 
before commencing on the current PI-based regimen. Five patients (16.7%) had high 
triglyceride levels after commencing on the current PI-based regimen. Twenty three 
patients (76.7%) did not have any documentation of high triglyceride. 
 
5.2.6    Deaths of patients on PI-based HAART regimens 
 
No death was recorded in the 35 respondents’ files.  This might have been a 
shortcoming of the study design because only records of patients attending the 
participating HIV clinic were studied. 
 
5.2.7    Reasons why patients were put on specific 2nd line HAART regimens 
 
Patients were started on their current PI-based regimens for reasons including failure on 
first line NNRTI-based regimens (68.5%; n=24), toxicity of NNRTI (14.2%; n=5 ) or prior 
PI-based regimens (n=3; 8.6%), to reduce pill burden of prior PI-based regimens (2.9%; 
n=3), pregnancy (5.7%; n=2), tuberculosis treatment (5.7%; n=2), transferred from other 
health care facilities already on PIs (5.7%; n=2) and in one patient’s file, the reason 
stated was “uncertainty”. Some of these patients were started on their current PI-based 
regimens for more than one of the recorded reasons. However, the records in the 
patients’ files did not indicate on which grounds any specific PI-based regimen was 
selected for a specific patient. 
 
Two patients were started on a PI-based regimen due to pregnancy. One patient 
defaulted several times but later became compliant several years after the pregnancy. A 
connection could not be made between her pregnancy and her regimen efficacy. The 
other patient was switched to the current PI-based medication just for the duration of the 
pregnancy, on regimen 1. She was previously on a successful NNRTI-based regimen 
before the pregnancy. She maintained high CD4 and undetected viral load, before, 
during and after the pregnancy.  There was no effect recorded of the pregnancy on her 
immunologic or virological status on the current PI-based regimen.  
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5.2.8   Patients’ periods of failing on 1st line HAART regimens before being 
changed to a PI-based HAART regimen 
 
There was no statistically significant difference in CD4 change percent based on prior 
regimens used (p= 0.143). All the patients were treatment experienced. Some had used 
NNRTI-based regimens only (n=14; 40.0%), a second group (n=14; 40.0%) had used 
both NNRTI and PI-based regimens, and a third group had previously used only PI-
based regimens (n=7; 20.0%). This question was also related to whether the patient 
changed all NRTIs when starting the current regimen, history of prior non adherence to 
PIs, history of switching PI-based regimens and history  of having confirmed failure to a 
previous regimen by virological, immunological and clinical findings.  
 
Changing all the NRTIs previously used when starting the current PI-based regimen did 
not make any statistically significant difference in CD4 change percent (p= 0.493). This 
means starting second line PI-based regimens is feasible in resource-limited settings 
with a limited number of available NRTIs, because these outcomes were similar to 
those of resource-rich countries where several alternative NRTIs are available. 
 
The 35 patients included in the study were split in two groups based on history of 
switching PI-based regimens; 1: yes previously switched PIs (f=8; 22.9%) and 2: no, did 
not previously switch PIs (f=27; 77.1%), and there was no statistical significance 
between the groups in CD4 change percent (P=0.108). Patients who had used other PI-
based regimens before the current one (8; 22.9%) were switched for  prior PI non 
availability (2; 25%), prior PI non adherence (2; 25%), commenced TB treatment (1; 
13%), side effects of prior PI-based regimens(3; 38) and at patients request (2; 25%), 
some cases being for more than one reason. None of the 8 (22.9%) patients who 
switched PIs were switched for failure of a previous PI-based regimen. Even though 2 
patients were switched for non-adherence to their regimens, this did not affect the 
efficacy of the subsequent PI-based regimen. This may have been due to the PI high 
genetic barrier to resistance. Resistance tests were not routinely done before starting 
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any new regimen so it could not be determined if there was any resistant mutations 
developed due to use of previous PI-based regimens. 
 
There were n=9; 25.7% patients who had never failed any regimens and n=26; 74.3% 
patients who had previously failed on NNRTI-based regimens. No patients failed on PI-
based regimens.  Having confirmed failure to a previous regimen did not affect CD4 
change percent in the current study (P=0.167). Having failed previous NNRTI-based 
regimens did not significantly affect CD4 change percent of current PI-based regimens. 
This was an expected finding because resistance to NNRTI has not been shown to 
confer resistance to PIs. 
 
There was no statistically significant difference in the CD4 baseline quadrants (p= 
0.961) and CD4 change percent (p= 0.697) when the patients were split in two groups 
based on whether they had been off ART (n=5, 14.3%) or not (n=30, 85.7%) for a short 
period before commencing the current PI-based regimens. The most likely reason was 
determined to be that these patients were not on successful regimens before their 
previous drugs were stopped, so they may have been comparable in their basal CD4 
quadrant to patients on ineffective HARRT who may also have been classified as being 
on  failing regimen just before the current PI based regimens. However patients on 
failing regimens in this research had lower baseline CD4 (P=0.02) and higher CD4 
change percent (p=0.03).It was expected that patients who were off ART for a period 
before commencing on their current PI-based regimens would have a lower baseline 
CD4 quadrant due to the natural progression of HIV/AIDS in which there is usually 
declining CD4 and rising viral load but the findings of this study did not show that trend. 
 
5.2.9   A comparison of the treatment outcomes of different PI-based regimens 
 
The CD4 and VL recovery of all 35 patients on PI-based regiments, included in this 
study, were of acceptable levels after 6 months’ treatment as all these patients had 
undetectable VL after 6 months’ treatment. The PI-based regimens in use at the SFGH 
have an acceptable level of efficacy. 
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The finding of higher efficacy of regimen 10 than 2 (TDF+FTC+LPV/r) (P=0.000) is 
significant (see table 4.5 indicating the CD4 change percent by regimens for eight PI-
based HAART regimens). Of note is that 23 patients were on regimen 2 while only 2 
were on regimen 10, so this difference might be due to under representation of regimen 
10. Both of the patients on regimen 10 were on failing regimens before starting their 
current regimens. Those patients on failing regimens had a higher CD4 change percent. 
This was also related to the significantly lower basal CD4 quadrant seen in patients who 
were on failing regimen just prior to their current PI-based regimens (P=0.021), and the 
finding that patients with lower basal CD4 had a significantly higher CD4 change 
percent than those with higher basal CD4 counts (P=0.000).  
 
To identify whether or not baseline CD4 acted as a confounding variable influencing the 
efficacy of the regimens, the basal CD4 of the regimens were compared.  There was no 
statistically significant difference (P= 0.323). Thus the baseline CD4 counts could not 
explain the differences in efficacy of the regimens. The theoretical assumption that 
patients with M184V mutations, from having failed 3TC or FTC, have reduced HIV 
replicative property and increased susceptibility to AZT, might explain the higher 
efficacy of regimen 10.  
 
The overall efficacy of the PI-based regimens was up to an acceptable standard. 
Patients on successful regimens were expected to have undetected VL by six months 
on HAART and CD4 increase of at least 50cells/mm3 after six months. In this study, all 
the patients had undetected VL by six months and the CD4 increase was M=65 
cells/mm3,   SD 100 after six months on the current PI based regimens. Two patients 
had virological blips at 12 months and 18 months on the current PI based regimens but 
these blips returned to undetectable levels after six more months on the PI-based 
regimens. There was no statistically significant incidence of viral blip by regimen 
(P=0.679). So none of the regimens were more likely than others to lead to regimen 
failure. The patient (male) who had a blip at 12 months (male) had a low level viraemia 
(VL=708 copies/ml) and the one who had it at 18 months (female) had a high viraemia 
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(1503 copies/ml), and she admitted to having unprotected sex with her HIV-positive 
partner at the time. This was an interesting finding but a conclusion was not drawn. 
 
5.3     LIMITATIONS OF THE STUDY 
 
Some limitations were encountered during data collection and analysis that might 
impact on the generalisability of the study’s findings. 
 
Only patients who attended one specific HIV clinic were included in this study.  The 
inclusive criteria specified that the patients’ should have been adherent to a PI-based 
HAART regimen for at least six months.  Consequently, the results cannot apply to 
patients who had been on such treatment regimens for less than six months or who had 
defaulted.  As only the patients receiving treatment at one clinic were included in this 
study, no records were found of patients who had died while on PI-based HAART 
regimens.   
 
No data analysis was available of the number of patients who were on PI-based HAART 
at the participating clinic. A manual count and categorisation was done to identify all 
patients aged 21 and older who were on PI-based regimens and who had been 
adherent on their medications for at least 6 months. Although 59 records identified 
which fit the inclusion criteria, only 35 patients’ records were included during analysis 
due to missing data.  This small number of records might influence the validity and 
reliability of the study’s findings.   
 
The literature review revealed several independent variables which could impact the 
outcome variables of this research, but which could not be addressed during the data 
analysis because the relevant information was missing from the patients’ files. Such 
missing information included patients’ WHO staging of AIDS as well as their height and 
weight measurements.  Changes in WHO staging and in patients’ weight might have 
added some significant measurable findings about the treatment outcomes of PI-based 
treatment regimens.  
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The study intended to study CD4 and VL counts at 6, 12 and 18 months’ duration of 
treatment on a specific PI-based HAART regimen.  CD4 and VL counts recorded at six 
months were analysed because it was the month with the least missing data.  The 
inability to evaluate these treatment outcomes after 12 and 18 months’ duration of 
treatment limited the significance of the current study’s findings.   
 
The analysis of both CD4 and CD8 changes could provide more accurate information 
about the CD4 change percentage, but the laboratory was incapable of determining 
CD8 counts.  Laboratory tests should in future establish whether or not patients do 
indeed show resistance to first line HAART regimens before changing them to second 
line regimens.  Such information was unavailable during the current study, making it 
impossible to identify 1st line HAART failure attributable to HIV resistance or to the 
patient’s non-adherence to the prescribed regimen. 
 
In the reviewed literature, where some data such as CD4 counts were missing, 
modelling and regression were used to compute the CD4 trajectory over time.  This was 
beyond the scope of the current study, compounded by the amount of missing data in 
the respondents’ files. 
 
Only information recorded in the patients’ files could be accessed and analysed.  More 
information might have been obtained by conducting individual interviews with the 35 
patients, but permission was not granted for interviewing patients. 
 
Initially the study aimed to conduct the survey in both Trinidad and Tobago, but no 
permission could be obtained to repeat the study in Tobago in time to meet the 
submission of this dissertation.  As this study was conducted as part fulfilment of the 
requirements for a masters in public health degree, funds were limited and the 
researcher could not afford to take unpaid leave to repeat the study in Tobago. 
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5.4    RECOMMENDATIONS 
 
The recommendations will be presented according to recommendations pertaining to 
the HIV services rendered at the participating clinic, and to future research projects 
focusing on patients on 2nd HAART regimens. 
 
Data recorded by the doctors in the participating HIV clinic should be improved and be 
more accurate. The patients’ height, weight and WHO staging should definitely be 
included.  At every clinic visit patients should be questioned about possible side effects 
and these answers must be recorded. Regular audits of patients’ files should be done 
and reports compiled and shared with the responsible doctors and other health care 
professionals at the clinic.  A monthly chart of such audits should be clearly displayed.  
Based on these monthly audits, the number of patients treated at the clinic on specific 
PI-based HAART regimens and their outcomes at 6, 12, 18 months should be recorded. 
Records should also be kept of patients who died while on PI-based HAART regimens 
and the causes of these deaths must be analysed. 
 
Patients who do not keep their clinic appointments should be contacted and assisted to 
continue with their HAART regimen, if possible.  Records of such follow-up actions 
should be maintained. 
 
In future, the laboratory should become capable of testing both CD4 and CD8 which 
would be useful in analysing CD4 changes. 
 
More studies need to be done to compare treatment outcomes of the 15 different PI- 
based HAART regimens.  Qualitative analysis should be included by gathering data 
directly from patients on their experiences of using specific PI-based regimens. 
 
5.5 CONTRIBUTIONS OF THE STUDY 
 
There were previously no data on PI-based HAART efficacy in the SFGH. This research 
is the first of its kind reported for the SFGH, Trinidad and Tobago.  
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Identification of all the limitations encountered while gathering the data brings 
awareness into how to improve the recording system in the department to enable future 
studies. 
 
5.6 CONCLUDING REMARKS 
 
Some important connections were revealed by the present study such as the higher 
efficacy of some PI-based regimens and the higher CD4 change percent with lower 
baseline CD4 quadrant. These however, are findings different from some other studies. 
Due to the poor quality of data recording and incomplete datasets, a definite conclusion 
cannot be drawn about the connections established in this study. A further study needs 
to be carried out, preferably a prospective cohort study in which data quality would be 
improved and the results would less likely be due to chance than actual significance. 
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 1 
Annexure  1: Checklist for data collection from patients’ records 
Checklist number: 
SECTION A: DEMOGRAPHIC AND MEDICAL INFORMATION 
1.1 Gender:      (a) Male     
                                                (b)   Female 
 1.2 Age 
 
 
 
 
 
 
 
 
 
 
1.3 Educational level completed: 
   
 
 
 
 
  
1.4   On second line ARVS at least six months? 
(a) Yes    (b) No 
21-25  
26-30  
31-35  
36-40  
40-45  
46-50  
51-55  
56-60  
61+  
None  
Primary  
Secondary  
Tertiary 
(please 
specify) 
 
 2 
                       
Questions 1.5 – 1.7 for women only  
1.5   Has she ever been pregnant since starting second line ARVs?  
                                                      (a) Yes     
                                                      (b)   No 
1.6.   If yes, how many times?  
                                                       (a) 1 
                                                       (b) 2 
                                                       (c) 3 
                                                       (d) 4 
                                                       (e) >4 (specify).....................  
 1. 7.   Did she stop ARVs during Pregnancy?        
                                                       (a) Yes    
                                                        (b)  No  
1. 8.  Has the patient had any other medical conditions apart from HIV? 
                                                (a) Yes   
                                                (b) No   
1.9.  If yes to 1.11, tick any from this list 
                                                   (a) Diabetes 
                                                   (b) Hypertension 
                                                   (c) Peptic Ulcer/GERD  
                                                   (d) Asthma 
                                                    (e) Epilepsy 
                                                    (f)  Liver disease 
                                                    (g) Heart disease  
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                                                    (h) Kidney disease  
                                                    ( i) connective tissue disease 
                                                    ( j ) previous splenectomy 
                                                    (k)  Cancer (Specify)……… 
                                                    (l)  Major Surgery 
                                                    (m) Acute infection (specify)……….. 
                                                     (n) Other (specify)…………         
SECTION B: ANTIRETROVIRAL HISTORY 
2.1 Current ARV regimen: 
     (a) 2a second line    
                        (b) 2b second line 
2.2         What was this patients’ first line regimen? 
 (a ) Truvada + EFV 
           (b ) Other combinations (Specify from the list following)....................... 
 
Date 
started 
      Drug 
Combination 
          Date stopped and why Any periods of 
interruption?(explain) 
    
    
    
    
    
    
    
    
    
Tenofovir (TDF), Emitricitabine (FTC), Lamivudine (3TC), Stavudine (d4T),Nevirapine (NVP), Efavirenz 
(EFV), Zidovudine (AZT)   
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2.3        When exactly was failure of first line suspected by the doctor?                                                            
 
 
 
2.4      How many months was the patient on the same first line regimen after  
            Failure was suspected ?   
                (a)    < 1month 
                (b)   1-2 months 
                (c)   2-3 months 
                (d)   3 months     
                (e) > 3months                                    
 
2.5       Was there any interval of no ARVs being used by this patient before  
             starting second line ARVs? 
                                            (a)  Yes           
                                            (b) No 
2.6       If yes to 2.7, how long was this interval? 
                (a)    < 1month 
                (b)   1-2 months 
                (c)   2-3 months 
                (d)   3 months     
                (e) > 3months                 
2.7 Mark any of the reason(s) below which may be the cause for changing to 
second line regimen (Note: more than one reason may be ticked) :   
   
dd/mm/yyyy 
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SECTION C: COUNSELLING AND ADHERENCE INFORMATION 
3.1      Was the patient adherent to first line ARVs before switching to the 2nd line  
           Regimen ? 
                                                  (a)  Yes           
                                                  (b) No 
 
3.2    If the response was ‘yes’ to question 3.1, please indicate how this adherence  
         was determined and the adherence level (if possible). 
                                                   (a) pill count 
                                                   (b) pharmacy refill date records 
                                                   (c) history from patient  
                                                   (d) Other (specify).................................. 
 
3.3 Was the patient counselled on adherence before second line ARV initiation?                                
                                        (a)  Yes          
                                                  (b) No 
 
 
Virologic failure (Increased VL)  
Immunologic failure (decreased 
CD4) 
 
Clinical failure  
Drug toxicity  
 Others (specify)                                          
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3.4     If yes to 3.3, how many adherence sessions did the patient attend? 
                                                       (a) 1    
                                                       (b) 2   
                                                       (c) 3   
                                                       (d) >3 
3.5  Pharmacy refill record  
   
 
 
   
  
 
 
                                                          
 
 
 
 
 
 
 
 
3.6. How many appointments has this patient missed at this clinic since        
starting treatment on second line?               
                                                       (a) 1    
                                                       (b) 2   
Pharmacy refill  
dates 
Number of months 
of  2nd line ARVs 
prescribed 
Dates when patient 
returned for refill 
1.   
2.   
3.   
4.   
5.   
6.   
7.   
8.   
9.   
10   
11.   
12.   
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                                                       (c) 3   
                                                       (d) >3 
 
3.7   Did the patient miss any medications since starting second line ARVs?  
                                                        (a) Yes  
                                                        (b) No 
 
3.8 If yes, what action did the patient take? 
                                (a) skipped the dose altogether       
                                (b) took the dose late         
                                (c) doubled the dose the next time he took his pills 
                                (d) Borrowed pills from another patient as his/her pills had finished 
                                (e) Other action (specify)...................................... 
 
3.9        Did the patient miss second line medications for any of the following  
             Reasons? 
Cause Yes No If yes, how 
many times? 
How long was 
he/she off for 
this reason? 
Felt better     
Clinic was not accessible (too far away )     
No money to go to the clinic     
Lack of food to take with medicines     
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3.10    Since starting taking second line ARVs has the patient visited any other 
kind of healer?                 (a) Yes  
                                                     (b) No   
 
3.11 If yes to 3.10, who?  (a)  Herbalist 
                                              (b)  Spiritualist 
                                              (c) Pastor/Priest 
                                              (d) Imam 
                                              (e)  Other (specify)..................................          
  
3.12 What treatment did the other healer recommend? 
 
Depressed     
Too many pills     
Lack of care/support     
Hospitalised ( too ill)     
Did not understand instructions      
Alcohol use     
Forgot     
Ran out of pills     
Side-effects     
Was in public place(fear of stigma)     
Alternative treatment(specify)     
Others (please specify)     
 9 
                                               (a)  Herbal medications 
                                               (b)  Prayers only 
                                               (c)  Sex with virgin 
                                               (d)  Healthy diet 
                                               (e) Multivitamins 
                                               (f)  Abstinence                         
                                               (g)  Other (specify)..................................          
 
SECTION D: SECOND LINE TREATMENT HISTORY 
4.1        Date initiated on second line regimen: 
                                                                          
 
                                          
4.2 Calculated duration of second line ARV treatment in months (at the point in  
           time the data was collected):   
    
 
 
 
 
4.3 CD4 cell count values: 
dd/mm/yyyy 
 
6 months  
12 months  
18 months  
 24 months or longer  
 CD4 CD4/CD8 
ratio 
CD4%                 
(dd/mm/yyyy) 
Baseline     
6months     
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4.4 Plasma Viral load:    
 
 
 
 
 
 
 
 
4.5   Clinical Stage: 
                                    
 
                                                    
 
     
 
 
 
 
 
 
12months     
18months     
24 months     
 Value Date 
(dd/mm/yyyy) 
Baseline   
6months   
12months   
18months   
24 months   
 Stage Date 
(dd/mm/yyyy) 
Baseline   
6months   
12months   
18months   
24 months   
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4.6 Weight: 
 
 
                      
 
 
 
 
 
 
4.7      Did the patient have any documented acute illness/ surgery/TB at the time 
           Of the blood tests referred to in questions 4.3 and 4.4?    
                                                        (a)  Yes           
                                                        (b) No 
 
 4.8       If yes to 4.7, was this illness Immune Reconstitution Inflammatory 
             Syndrome? 
                                                         (a)  Yes      
                                                         (b)  No  
 
 
 
 
 
 
 Value Date 
(dd/mm/yyyy) 
Baseline   
6months   
12months   
18months   
24 months   
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 4.9      What was the presentation of the illness and at what month on second  
            Line treatment? 
Presentation Baseline 6months 12 
months 
18 
months 
24 
months 
Other 
Fever       
Rash (specify type of rash )       
Diarrhoea       
Cough/Pneumonia/TB 
(specify) 
      
Meningitis       
Others(specify)       
 
                               
 4.10   What other medications/drugs (besides ARVs) were prescribed for this  
         patient since starting second line ARVs?  Please write the name of the  
         prescribed drugs in the appropriate block in the table below. 
Tick 
(date 
started) 
Drug How many 
times per day? 
Duration of 
use? 
 Pain killers   
 Appetite stimulants/vitamins   
 Sleeping pills   
 TB treatment   
 Antibiotics   
 Fungal infection treatment   
 Corticosteroids   
 Interferon   
 Cancer treatment (specify)   
 Others   
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4.11       Was the patients regimen switched from 2a to 2b on account of failure on  
             2a?                                (a) Yes 
                                                  (b) No 
4.12  If yes to 4.9, what date exactly was this? ...................................... 
 
SECTION E: SIDE EFFECTS 
5.1       Has the patient experienced side-effects to the second line ARV regimen? 
                                              (a) Yes   
                                              (b)  No 
5.2       If yes to 5.1, tick the side effects below (more than one may be  
            ticked) 
      
Side effects Yes No If yes, how 
many times 
Treatment/management 
of each side-effect 
Nausea     
Vomiting     
Diarrhoea     
Headache     
Skin Rash     
Dizziness     
Depression     
Skin or nail discolour     
Anaemia     
Others (please specify)    
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     5.3          Documented anaemia on second line ARVs?   
                                           (a)  Yes  
                                           (b) No 
 
    5.4          What were the Hgb levels and number of months on second line when 
                    the tests were done? 
  
 <3mg/dl 4-5mg/dl 6-7mg/dl 8-9mg/dl >10mg/dl 
Baseline      
1month      
2months      
3months      
6months      
12months      
18months      
24months      
                             
 5.5        Was the 2b Regimen switched to 2a on account of any side effect? 
                                          (a)  Yes  
                                          (b) No                                
5.6.   If yes to 5.5, Please specify the side effect 
Side effects Yes No If yes, how 
many times 
Treatment/management 
of each side-effect 
Nausea     
Vomiting     
Diarrhoea     
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   5.7    If yes to 5.5, how many months on second line 2b HAART was this?  
                 (a)   < 1month 
                (b)   1 month 
                (c)   2 months 
                (d)   3 months     
                (e) > 3months (specify)..............................               
5.8   Was the side effect resolved after switching 2b to 2a regimen? 
                                         (a) Yes    
                                         (b) No  
5.9            If there was anaemia due to 2b, and 2b was switched to 2a, how long  
                 Did the patient continue 2b before switching to 2a? 
                                           (a)   < 1month 
                                           (b)   1 month 
                                           (c)   2 months 
                                           (d)   3 months     
                                           (e) > 3months (specify)..............................       
 
Headache     
Skin Rash     
Dizziness     
Depression     
Skin or nail discolour     
Anaemia     
Others (please specify)    
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5.10        Wes there any period of no ARVs taken before switching 2b to 2a? 
                                             (a) Yes 
                                             (b) No          
5.11        What were the Hb levels after switching 2b to 2a and number of months  
               After switching it got to this level? 
 <3mg/dl 4-5mg/dl 6-7mg/dl 8-9mg/dl >10mg/dl 
1month      
2months      
3months      
6months      
12months      
18months      
24months      
  
 
5.12        What other action was taken to correct the anaemia ? 
                                (a) dietary measures 
                                (b) hematinics 
                                (c) blood transfusion 
                                (d) Other (specify)  
   
 
 
===================================================================================== 
Annexure 3: Permission letter to the Ministry to conduct the research 
 
                                                                            c/o Amanda Taylor 
                                                                            United Nations Volunteers   
UNDP 
42 Brickdam and Un Place 
Georgetown 
……………….2012 
 
The Chairman 
Research and Ethics Committee  
Ministry of Health 
Guyana 
 
Dear Sir/Madam, 
 
 PERMISSION TO CONDUCT RESEARCH AT NATIONAL CARE AND TREATMENT  
CENTER (NCTC). 
 
I am a medical doctor registered with the Ministry Of health of Guyana. I am a 
registered MPH student at the University of South Africa (UNISA).   
 
I request permission to conduct research at NCTC, Guyana. This research is part of the 
requirements for completing the MPH (Master’s in Public Health) degree at the 
Department of Health Studies, University of South Africa (Unisa), Pretoria. My Unisa 
student number is 37335056. Please find attached letter from the Research and Ethics 
Committee, Department of Health Studies, UNISA, granting ethical clearance for 
conducting this study. 
 
study such as this will contribute to the existing body of the knowledge about HAART 
efficacy.  No other study could be traced that compared the treatment outcomes of 2a 
and 2b HAART regimens.  Only checklists will be used to collect data from the records 
of patients on 2a and 2b HAART. The researchers will collect all data personally. The 
completed checklists will be kept under lock and key.  Only the researcher, the study’s 
supervisor and the statistician will have access to the raw data.  No patient’s name will 
be recorded on the completed checklist, only a new respondent number.  The 
researcher will keep a list correlating each respondent number with a specific patient 
number, in case queries need to be addressed.   Only the researcher will have access 
to this list and it will be locked up in a secure place.  After the report has been accepted, 
this list will destroyed and all completed checklists as well. 
 
No patients and no staff members will be interviewed or asked to complete 
questionnaires.  Consequently data gathering from the patients’ records should not 
impact negatively on the functions of the clinic and should not impact on patients or staff 
in any manner whatsoever. 
 
The findings of the study will be communicated to your office, to the NCTC and to the 
healthcare providers at the participating site, after it has been accepted by the 
University of South Africa. 
 
I shall be very pleased if you could grant me the permission to carry out the study. 
Should you have any queries, please do not hesitate to contact me or my supervisor on 
the contact details provided below. 
 
Yours faithfully, 
 
 
 
Dr Elohor Ziregbe. (Researcher: +1 868 350 3198) 
 
Prof. VJ Ehlers (Supervisor: 0027 12429 6731) 
 
 
 
 
 
 
 
       Annexure 3b: Permission Letter to the Institution to conduct research 
 
                                                                           
                                                                            c/o Amanda Taylor 
                                                                            United Nations Volunteers   
UNDP 
42 Brickdam and UN Place 
Georgetown 
……………….2012 
 
The Medical Director, 
National Care and treatment Center, 
Thomas Street, 
Georgetown, 
Guyana. 
Dear Madam, 
 
 PERMISSION TO CONDUCT RESEARCH 
 
 
I am a medical doctor registered with the Ministry Of health of Guyana. I am also a 
registered MPH student at the University of South Africa (UNISA).  Please find attached 
letter from the Research and Ethics Committee, Department of Health Studies, UNISA, 
granting ethical clearance for conducting this study. 
 
I wish to apply for permission to carry out a study to compare the efficacy of two highly 
active antiretroviral treatment regimens at the National Care and Treatment Center, in 
Guyana. This is part of the requirements for the completion of my MPH (master’s 
degree in public health). 
 
A study such as this will contribute to the existing body of the knowledge about HAART 
efficacy.  No other study could be traced that compared the treatment outcomes of 2a 
and 2b HAART regimens.  Only checklists will be used to collect data from the records 
of patients on 2a and 2b HAART. The researchers will collect all data personally. The 
completed checklists will be kept under lock and key.  Only the researcher, the study’s 
supervisor and the statistician will have access to the raw data.  No patient’s name will 
be recorded on the completed checklist, only a new respondent number.  The 
researcher will keep a list correlating each respondent number with a specific patient 
number, in case queries need to be addressed.   Only the researcher will have access 
to this list and it will be locked up in a secure place.  After the report has been 
accepted, this list will destroyed and all completed checklists as well. 
 
No patients and no staff members will be interviewed or asked to complete 
questionnaires.  Consequently data gathering from the patients’ records should not 
impact negatively on the functions of the clinic and should not impact on patients or 
staff in any manner whatsoever. 
 
The findings of the study will be communicated to your office and to the healthcare 
providers at the participating site, after it has been accepted by the University of South 
Africa. 
 
I shall be very pleased if you could grant me the permission to carry out the study. 
Should you have any queries, please do not hesitate to contact me or my supervisor on 
the contact details provided below. 
 
Yours faithfully, 
 
 
Dr Elohor Ziregbe. (Researcher: +1 868 350 3198) 
 
Prof. VJ Ehlers (Supervisor: 0027 12429 6731) 
